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Abstract
Non-competitive NMDA receptor antagonists, such as phencyclidine (PCP) and
dizocilpine (MK-801) can even acutely induce a drug induced psychotic state which
closely resembles schizophrenia. The midbrain dopamine (DA) neurons, which originate
in the ventral tegmental area (VTA), are involved in motivational, attentional and
cognitive processes, and have also been profoundly implicated in schizophrenia.
Therefore, the present work analyzed the effects of these psychotomimetics on the
mesocorticolimbic DA neurons in the rat, and associated behavioral significance, as well
as the potential reversal of these effects by different types of drugs; the objectives being
to reveal potential pathophysiological mechanisms underlying psychotic states and to
assist the development of improved pharmacotherapy in schizophrenia.
DA neuronal activity was studied by means of single cell recordings in vivo and
DA and neurotensin (NT) release in nerve terminal regions was assessed with
microdialysis in freely moving animals coupled to HPLC and RIA methodology.
Behavioral techniques included measurements of locomotor activity, conditioned
avoidance response (CAR) and catalepsy. Systemic administration of PCP and MK-801
produced an increased firing rate and decreased variability of firing in DA neurons. Burst
firing was differentially affected in different subpopulations of VTA DA cells. A high
frequency, burst-like firing pattern was obtained in neurons projecting to subcortical
sites, e.g. to the nucleus accumbens (NAC). In contrast, burst firing was attenuated in
DA cells which largely project to the medial prefrontal cortex (MPFC). PCP increased
release of DA and the colocalized peptide NT in both the ventral striatum and the
MPFC. The MK-801 evoked DA output in the NAC was antagonized by inhibition of
DA nerve impulse generation or by local antagonism of AMPA and kainate receptors in
the VTA, a procedure which also blocked the locomotor stimulation. The MK-801
evoked DA output in the MPFC was, in contrast, not affected by inhibition of nerve
impulses in the VTA. Pretreatment with the a1-adrenoceptor antagonist prazosin also
antagonized the MK-801 induced increase in DA output in the NAC, and the associated
locomotor stimulation. Finally, systemic administration of the AMPA receptor
antagonist LY326325 was found to specifically suppress the CAR without affecting
escape behavior, and did not cause catalepsy.
PCP and MK-801 thus profoundly dysregulate mesocortical and mesolimbic DA
neurons in a differential manner. The drugs cause a pronounced augmentation of
mesocortical DA output that is independent of nerve impulse activity and instead is
mediated at the nerve terminal level. In contrast, a nerve impulse dependent increase in
mesolimbic DA output is obtained by systemic MK-801 that seems elicited in the VTA
by AMPA and/or kainate receptor activation. Since both the a1-adrenoceptor antagonist
and the AMPA receptor antagonist effectively reversed several of the behavioral and
biochemical correlates to the dysregulated mesocorticolimbic DA system, induced by
PCP-like drugs, an antipsychotic potential of both types of drugs is indicated, which is
especially supported for LY326325 by the suppression of the CAR.
Keywords: phencyclidine, MK-801, CNQX, prazosin, tetrodotoxin, dopamine,
neurotensin, ventral tegmental area, nucleus accumbens, medial prefrontal cortex.
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Cover illustration: Sketch of a visual hallucination. 
by anonymous, a catatonic schizophrenic.
To my family
'Twas brillig, and the slithy toves
Did gyre and gimble in the wabe;
All mimsy were the borogoves,
And the mome raths outgrabe.
Excerpt from 'Jabberwocky'
Through the Looking Glass
Lewis Carroll
nom de plume of Charles Lutwidge Dodgson (1832-1898)
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9Abbreviations
5-HT Serotonin
AMPA a-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid
CAR Conditioned avoidance response
CNQX 6-cyano-7-nitroquinoxaline-2,3-dione
CS Conditioned stimulus
EAA Excitatory amino acid
EPS Extrapyramidal side effects
DA Dopamine
DOPAC Dihydroxyphenylacetic acid
HVA Homovanillic acid
LC Locus coeruleus
MK-801 Dizocilpine
MPFC Medial prefrontal cortex
NAC Nucleus accumbens
NMDA N-methyl-D-aspartate
NT Neurotensin
NT-LI Neurotensin-like immunoreactivity
PBP Parabrachial pigmented subdivision of the ventral tegmental area
PET Positron emmision tomography
PFC Prefrontal cortex
PCP Phencyclidine
PN Paranigral subdivision of the ventral tegmental area
SN-ZC Substantia nigra, zona compacta (A9)
TTX Tetrodotoxin
UCS Unconditioned stimulus
VSTR Ventral striatum
VTA Ventral tegmental area (A10)
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Introduction
Schizophrenia
Schizophrenia is one of the most debilitating psychiatric disorders and affects
approximately 1% of the population worldwide. The onset of the disease most
frequently occurs during the late teens and twenties, and episodes recur throughout life,
disrupting the individuals’ most productive years. It is mostly characterized by marked
distortions of the perception of reality, disturbances of intellectual functions, motivation
and affect as well as motor aberrations. The etiology of schizophrenia is unknown, and
there is strong indication for hereditary linkage (see Gottesman 1991). During the 1980s
a neurodevelopmental perspective gained increased attention. Thus, schizophrenia might
represent a long term consequence of an early, prenatal abnormality in neural
development, which lies dormant until an affected region matures and is called upon to
function (Weinberger 1987). Contributing factors could, for example, include a viral
infection or maternal stress during pregnancy which, in turn, might interact with a
genetic predisposition. Indeed, both experimental and neurohistochemical clinical
studies have provided support for this hypothesis (see e.g. Jakob & Beckman 1986,
Arnold et al. 1991, Akbarian et al. 1993, Lipska & Weinberger 1995, Lipska et al. 1995,
Selemon et al. 1995, Weinberger 1995, Akbarian et al. 1996) Apparently, schizophrenia
may be a heterogenous disorder, which is the result of several pathological processes,
including structural, biochemical and functional abnormalities in brain.
The symptoms are commonly divided into three principal clusters (see
Andreasen 1990). The so-called positive symptoms of schizophrenia include the more
florid expression of the disorder, such as delusions, bizarre behavior and perceptual
distortions, as well as auditory or visual hallucinations. In contrast, negative symptoms
represent a decrease or loss of normal functions and include e.g. poverty of speech,
blunting of emotions, amotivation, loss of sociability and anhedonia. In addition,
schizophrenia is usually associated with several neuropsychological deficits, such as
cognitive impairment, lack of insight and poor judgement. Afflicted individuals may
exhibit grossly disorganized behavior and an inability to take care of their basic daily
needs and, consequently, voluntary or involuntary hospitalization is not infrequently
required. The combinations of symptoms may vary significantly in schizophrenia, as may
the course of the disorder.
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In spite of efficient antipsychotic medications coupled to psychosocial measures,
a substantial number of schizophrenics do not recover completely and many
schizophrenic patients lead impoverished lives. The cost of treatment of schizophrenia,
as well as loss of income has been estimated to approximately $40 billion per year in the
United States (Rupp & Keith 1993). Consequently, the need to improve therapy for this
disorder is considerable not only from a medical perspective, but also for economical
reasons. Development of more efficient pharmacological treatment requires a better
understanding of the pathophysiological mechanisms involved. This task has proven
difficult to achieve as reflected by the fact that to date, the only common denominator
identified for the mechanisms of action of all drugs known to exert a therapeutic effect
in schizophrenia is antagonism of dopamine (DA) mediated neurotransmission in brain.
Such antagonism can be achieved either at the presynaptic level, as exemplified by
reserpine, or at the postsynaptic level, as exemplified by all presently used antipsychotic
drugs. Consequently, during the past forty years the neurotransmitter dopamine has
remained at center stage in neurobiological research and drug development in this
medical area.
Dopamine
Dopamine Systems
Dopamine was discovered as an independent neurotransmitter in brain during
the late 1950s (Carlsson et al. 1957, 1958, Carlsson 1959). The mesotelencephalic DA
systems (Fig. 1) originate in the midbrain tegmentum and the distribution of DA cell
bodies in this region is restricted largely to two nuclei in the rat; the substantia nigra
zona compacta (SN-ZC or A9) and the ventral tegmental area of Tsai (VTA or A10), as
revealed by Dahlström and Fuxe (1964). The neurons in the SN-ZC project primarily to
the caudate nucleus and putamen, i.e. striatum, and the system was thus called the
nigrostriatal DA system (Andén et al. 1964). The VTA exhibits somewhat more diverse
projections than the SN-ZC. Thus, the DA neurons in the VTA project to e.g. ventral
striatum (VSTR) including the nucleus accumbens (NAC), amygdala, hippocampus,
olfactory tubercle as well as several limbic cortical sites, such as medial prefrontal,
cingulate and entorhinal cortices (Andén et al. 
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Fig. 1: Schematic drawing of the major dopamine-containing pathways in the rat
brain (From Cooper et al. 1996).
1966B, Ungerstedt 1971A, Björklund and Lindvall 1984). In man, the cortical DA
projection is much more widespread than in the rat, corresponding to the relatively
larger size of the frontal cortex in humans. These DA pathways are often collectively
referred to as the mesolimbocortical DA system. However, cortically projecting DA
neurons appear not to innervate subcortical sites, and vice versa (Fallon 1981, Swanson
1982). These cortical and subcortical DA projections seem, at least partially, to arise
from different anatomical subdivisions of the VTA. The ventrally located paranigral
nucleus (PN) of the VTA primarily contributes the subcortical, mesolimbic DA
projection, e.g. to the NAC and other striatal sites. In contrast, the parabrachial
pigmented nucleus (PBP) of the VTA also contains the somata of DA neurons from
which the cortical DA innervation originates (Simon et al. 1979, Deniau et al. 1980,
Fallon 1981, Swanson 1982, Oades & Halliday 1987, Phillipson 1989). In addition, these
mesocortical DA neurons exhibit several functional differences from the mesolimbic
DA cells; mesocortical DA neurons display a more variable firing pattern, differential
coexistence with neuropeptides, as well as altered autoreceptor and heteroreceptor
regulation in comparison with the subcortically projecting DA neurons (see Grenhoff et
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al. 1988A, Roth & Elsworth 1995).
Dopaminergic receptors are broadly divided into two families: the D1 receptor 
family (i.e. D1 and D5) stimulates the formation of cyclic adenosine 3',5'-monophosphate
(cAMP), whereas the D2 family (D2, D3 and D4) inhibits the formation of cAMP. Both
D1 and D2 families are found postsynaptically, whereas the presynaptic receptors are
regarded to belong to the D2 family. There appears to be some differential distribution
of DA receptor types in various DA terminal regions in the rat. Dense D1 binding has
been found in the dorsolateral striatum and moderate binding has been detected in the
neocortex (Boyson et al. 1986).  Dense D5 binding is mainly restricted to thalamic,
hypothalamic and hippocampal neurons. High D2 binding is observed e.g. in 
dorsolateral striatum, NAC, VTA and SN-ZC (see Gehlert & Wamsley 1985). D3
receptor binding is generally less abundant than D2 receptor binding, although dense
binding was found in the NAC shell subdivision, as well as in the islands of Calleja
(Lévesque et al. 1992).  Finally, D4 receptors have been shown to be localized largely in
limbic cortical sites in man, and have been considered as a potentially important binding
site for atypical antipsychotics (see Seeman 1990, van Tol et al. 1991). D4 receptors
appear not to have been reliably detected in the rat brain (for review see Mansour &
Watson 1995). However, some functional roles for this receptor have been described
(Merchant, personal communication).
Dopaminergic neurotransmission
Dopamine is synthesized from the amino acid tyrosine in a two-step enzymatic
process. First, tyrosine is converted to L-dihydroxyphenylalanine (L-DOPA) by the
enzyme tyrosine hydroxylase, which is the rate-limiting enzyme in DA synthesis.
Subsequently, L-DOPA is rapidly converted to DA by aromatic L-amino acid
decarboxylase. In noradrenergic neurons, DA is further converted by dopamine ß-
hydroxylase to noradrenaline. DA is stored in vesicles and physiologically released by a
calcium-dependent process initiated by nerve impulse activity. Released DA is to
approximately 80% very effectively and rapidly transported back into the nerve terminal
by a DA-specific transporter. Extravesicular DA is intracellularly metabolized by the
enzyme monoamine oxidase (MAO) to dihydroxyphenylacetic acid (DOPAC). Released, 
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Fig. 2: Oscillgraphic traces of the two main modes of midbrain DA
cell firing, i.e. single spike firing (A) and burst firing (B).
extracellular DA is sequentially degraded by the actions of catechol-O-methyl transferase
(COMT) and MAO to 3-methoxytyramine (3-MT) and homovanillic acid (HVA). In the
rat brain DOPAC is the major DA metabolite. Nevertheless, both DOPAC and HVA,
in both sulfate-conjugated and free forms are found in high concentrations, along with
small amounts of 3-MT, in rat brain. In human brain, free HVA appears instead as the
main metabolite, with only small amounts of DOPAC (see Cooper et al. 1996).
Physiology and regulation of dopaminergic neurons
The impulse activity of DA neurons in the SN-ZC and VTA is characterized by
two differential modes of firing; single spike firing and burst firing (Fig. 2; see Wang et
al. 1991, Grace and Bunney 1983, 1984). Single spike firing is a relatively regular, low
frequency firing pattern, i.e. between 1-10 Hz. In contrast, burst firing is typically
recognized as the transient high-frequency discharge of multiple action potentials. The
burst firing mode has been shown to elicit much more efficient release of DA in 
terminal areas than a regular firing pattern of the same average rate, and burst firing also
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Fig. 3: Effects of regular and burst stimulation of the same average frequency on 
release of DA  (A) and on Fos expression in postsynaptic neurons (B). Specifically, 
burst stimulation  was up to six times as effective as regular stimulation with the 
same number of pulses in causing DA release, and only burst stimulation caused 
significant increase in the number of Fos-positive nuclei e.g. in the NAC shell 
subdivision, an effect blocked by administration of the D1 receptor antagonist, 
SCH23390 (Adapted from Gonon 1988 (A) and Chergui et al. 1996 (B)).
causes significant activation of postsynaptic neurons (Fig. 3, Gonon 1988, Bean & Roth
1991, Suaud-Chagny et al. 1991, Chergui et al. 1996). However, this pulse of DA
produced by a burst of action potentials is rapidly attenuated by efficient uptake of
transmitter from the synaptic cleft (Grace & Bunney 1984). In addition, bursts seem to
specifically facilitate release of colocalized neurotransmitters, such as neurotensin (NT)
and cholecystokinin (Bean & Roth 1991). Such transient changes in impulse activity
normally occur in relation to basic attentional and motivational processes in response to
reward-predicting stimuli, and apparently serve to initiate goal-oriented behaviors
(Schultz 1986, Nishino et al. 1987, Schultz et al. 1993, Schultz 1998). In both awake and
anesthetized mammals in vivo, DA cells typically display a firing pattern which includes
both single spike and burst firing, with frequent switches between these two modes of
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firing (Grenhoff et al. 1988A). In contrast, in DA cells in a midbrain slice preparation,
i.e. in cells that have been largely deprived of active neuronal inputs, burst firing is
absent and little variability in the firing pattern is observed (Grace & Onn 1989).
Generally, the structure of the firing patterns of midbrain DA neurons in vivo has been
proposed to reflect the neurons response to coordinated synaptic inputs emerging from
neuronal circuit interactions (Hoffman et al. 1995) Consequently, in view of the
behavioral deficits in schizophrenia, which include both attentional dysfunction and
anhedonia as well as severely impaired goal-oriented behaviors, the dynamic,
physiological responsivity of mesocorticolimbic DA cells appears to be of prime interest
as a potential dysfunctional mechanism in the pathophysiology of schizophrenia
(Svensson & Tung 1989, see Svensson et al. 1995).
The general physiological and biochemical activity of DA neurons originating in
the midbrain is profoundly regulated by DA receptors. The original experiments by
Carlsson and Lindqvist (1963), which studied antipsychotic drug action utilizing
biochemical methodology, proposed a feedback regulation of DA neuronal activity by
postsynaptic DA receptors. This notion was subsequently confirmed by several
electrophysiological studies (see Aghajanian & Bunney 1973, Bunney et al. 1973,
Aghajanian & Bunney 1977, Bunney & Aghajanian 1978, Einhorn et al. 1988). Moreover,
DA activity is also controlled by the so-called autoreceptors, i.e. various DA receptors
located along the DA cells responding to the neuron’s own neurotransmitter by an
inhibition of transmitter synthesis and release, as well as of the firing rate. Conversely, a
stimulation of DA activity is observed following administration of DA-D2 receptor
antagonists (Kehr et al. 1972, Andén et al. 1973, Roth 1973, Bunney & Aghajanian 1973,
for review see Carlsson 1977, Roth & Elsworth 1995). Activation of somatodendritic
autoreceptors by DA or DA agonists, such as apomorphine, hyperpolarize DA neurons
through opening of K+ channels via a pertussis toxin sensitive G-protein (Aghajanian
and Bunney 1973, Innis & Aghajanian 1987, Lacey et al. 1987). Release of DA seems also
to be modulated by presynaptic DA autoreceptors located on the nerve terminals, since
local or systemic administration of DA agonists has been reported to decrease DA
release in the striatum (Kehr et al. 1972, Zetterström & Ungerstedt 1984, Westerink &
de Vries 1989). However, mesocortical DA neurons appear largely to lack nerve impulse
and synthesis
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Fig. 4: Oscillographic traces of the effects of local microiontophoretic application 
of NMDA (A) or kainate or quisqualate (B) on the firing pattern of VTA DA 
neurons. Local NMDA application evoked typical bursts of action potentials. In 
contrast, kainate or quisqualate application caused a high-frequency, burst-like firing 
pattern in VTA DA cells (Adapted from Chergui et al. 1993).
modulating autoreceptors (Chiodo et al. 1984, see Roth and Elsworth 1995).
Spontaneous burst activity of DA neurons appears to be directly dependent
upon activation of somatodendritic N-methyl-D-aspartate (NMDA) receptors via
afferent excitatory amino acid (EAA) inputs from e.g. the prefrontal cortex (PFC) and
subthalamic nucleus (Fig. 4; Christie et al. 1985, Sesack et al. 1989, Bayer & Pickel 1990):
these regions seem directly involved in the control of burst firing and, secondarily, also
in the release of DA in terminal regions (Gariano & Groves 1988, Grenhoff et al. 1988B,
Svensson and Tung 1989, Charléty et al. 1991, Chergui et al. 1993, Murase et al. 1993,
Chergui et al. 1994). In addition, the NMDA receptors are involved in the control of the
regularity of firing, another functionally important determinant of DA neuronal
discharge (see Grenhoff et al. 1988B, Servan-Schreiber et al. 1990). Biochemical support
for differential regulation of VTA DA neuronal subpopulations by EAAs was reported
in the late 1980s. Thus, although DA release in the PFC was found to be preferentially
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modulated by NMDA receptors in the VTA, the DA release in the NAC seemed largely
controlled by AMPA and kainate receptors in the VTA (Kalivas et al. 1989). The firing
pattern of VTA DA cells was demonstrated to be influenced also by ?-amino butyric
acid (GABA) receptors; GABAB receptors hyperpolarize VTA DA neurons by
inhibition of voltage-dependent Ca2+ conductance and thus reduce the average firing rate
and attenuate burst firing (Grace & Bunney 1980, Johnson & North 1992). Furthermore,
burst activity of VTA DA neurons seems to be modulated by a noradrenergic input
from the locus coeruleus (LC) to the VTA. Thus, administration of the a1-adrenoceptor
antagonist prazosin selectively depresses burst firing (Grenhoff et al. 1993). Electrical
stimulation of the LC elicits monoamine mediated short latency bursts in VTA DA cells,
an effect that in turn was specifically antagonized by prazosin administration (Grenhoff
& Svensson 1993). Stimulation of a1-adrenoceptors seems to increase the excitability of
DA cells via inhibition of K+ efflux (Grenhoff and Svensson 1993, Grenhoff et al. 1995).
Neurotensin
 In rats, VTA neurons contain one or both of the neuropeptides cholecystokinin
and the tridecapeptide neurotensin (NT) in neurons projecting to various structures in
the limbic forebrain including the frontal cortex and ventral striatum (VSTR, see Hökfelt
1991). Some of these NT containing neurons have been shown to contain also DA
(Hökfelt et al. 1984). In these mixed DA/NT neurons, which largely originate in the
PBP subdivision of the VTA, a subpopulation projects to the medial prefrontal cortex
(MPFC), a region where the majority, if not all, fibers contain both DA- and NT-
immunoreactivity (Seroogy et al. 1987, Studler et al. 1988, Jayaraman et al. 1990). The
VSTR, including the NAC, also receives both DA and NT projections from the VTA,
although colocalization appears comparatively less abundant than in the MPFC. NT is
thought to be stored in large dense-core vesicles, but not in small vesicles found in DA
terminals. NT is released, like DA, in a Ca2+ and action potential dependent manner
(Bean et al. 1989A, B, C). Differential storage of DA and NT is consistent with the
finding that low frequency regular stimulation of DA axons selectively releases DA,
whereas high frequency or burst stimulation has been shown to release both DA and
NT (see Hökfelt 1991, Bean & Roth 1991). This property of the mixed DA/NT
neurons may allow differential transmitter release under different functional conditions.
NT binding sites have been found on
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cell bodies in the VTA, as well as in many projection areas of the mesolimbic and
mesocortical DA systems, where they appear to be located mostly at postsynaptic sites.
NT seems to play a modulatory role as regards VTA DA neuronal activity as well
as on the effects of DA in terminal regions. Thus, NT microinjection into the VTA was
found to stimulate DA cell firing rate (Seutin et al. 1989), and caused a concomitant
increase in DA output in the NAC (Blaha et al. 1990). These functional effects were
accompanied by an increase in locomotor activity (Kalivas et al. 1983). Conversely, NT
injections into the NAC were reported to cause a decrease in NAC neuronal activity and
to antagonize the locomotor stimulation caused by indirect DA agonists (McCarthy et al.
1979, Ervin et al. 1981). NT neurons, in turn, are subject to dopaminergic regulation.
Early studies showed that administration of DA-D2 receptor antagonists increases tissue
levels of NT in several discrete brain nuclei, including the NAC (Govoni et al. 1980,
Goedert et al. 1985). 
The coexistence of DA and NT has not been observed in primates (Berger et al.
1991). Some early clinical studies indicated that certain subgroups of schizophrenic
patients have decreased concentrations of NT in cerebrospinal fluid (CSF) with
normalization after neuroleptic treatment (Widerlöv et al. 1982, Garver et al. 1991). In
addition, a correlation between CSF NT concentrations and deficit symptoms in
schizophrenia was later observed (Breslin et al 1994). In fact, NT has even been
suggested to act as an endogenous neuroleptic (Lipton et al. 1979, Nemeroff 1980).
Thus, NT may serve to modulate the function of mesolimbic and mesocortical DA
neurons, although the role of NT in normal brain function as well as in psychiatric
disorders is still far from clear. 
Functional roles of the mesolimbic and mesocortical DA systems
Generally, the mesolimbic and mesocortical DA systems are involved in major
behavioral functions such as motivation, emotional control and cognition (see Le Moal
& Simon 1991), processes which are of prime interest in schizophrenia. 
A massive set of experimental evidence supports the contention that the ventral
striatum, including the NAC, plays a role in the control of motivation, emotion and
ongoing behavior, including locomotion in rodents (see Mogenson 1987). Specifically,
the mesolimbic DA system is regarded to be directly involved in these behavioral
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functions. Indeed, stimulation of the VTA initiates locomotion (Koob & Swerdlow
1988). Furthermore, increases in locomotor activity caused by administration of several
DA releasing psychostimulants, e.g. D-amphetamine and cocaine, are attenuated by
lesioning of DA terminals within the NAC using the neurotoxin 6-hydroxydopamine
(Wise and Bozarth 1987). Furthermore, similar lesions of DA terminals in the NAC
attenuate self-administration of several drugs of abuse (Pfeffer & Samson 1988, Panocka
et al. 1993), documenting a role of mesolimbic DA in the reinforcing properties of these
drugs. In fact, not only DA cell firing but also the DA output in the NAC increase in
response to rewarding stimuli, such as feeding or sexual behavior (Schultz et al. 1986,
Nishino et al. 1987, Smith & Schnieder 1988, Fibiger et al. 1992, Westerink et al. 1997).
These findings support involvement of DA both in appetitive and in consummatory
aspects of motivational behaviors. In addition, the mesolimbic DA pathway to the
ventral striatum appears to be of critical importance for the initiation of active avoidance
behavior (Wadenberg et al. 1990, see Le Moal & Simon 1991). Interestingly, recent
studies indicate that the mesolimbic DA system also may play a role in the development
of long-term potentiation in corticostriatal synapses, indicating an important function of
the mesolimbic DA system in learning (see Arbuthnott et al. 1998).
The PFC is generally involved in integrative functions, including cognitive
processes, such as maintenance of focused attention, working memory, as well as
planning and execution of behavior, processes that are modulated by the mesocortical
DA system. Mild stressors have been shown to cause a preferential activation of the
mesocortical DA neurons (Thierry et al. 1976, see Le Moal & Simon 1991), but also
reward related stimuli augment mesocortical DA output (Taber & Fibiger 1997).
Importantly, DA is involved in the gating of inputs to the PFC, e.g. afferents that
originate in the mediodorsal nucleus of the thalamus (Ferron et al. 1984, see Thierry et
al. 1998). Significantly, activation of D1 receptors in the PFC may represent a critical step
in the performance of tasks requiring working memory (Sawaguchi & Goldman-Rakic
1994). Also computer simulations of PFC circuitries suggest that DA plays a major role
in the gating of excitatory and inhibitory inputs, i.e. regulation of the responsiveness or
signal-to noise ratio of cortical neurons to afferent inputs (Servan-Schrieber et al. 1990,
Hoffman & McGlashan 1993). Thus, from a behavioral standpoint, the mesocortical DA
system appears critical for the precise control of focused attention, short term memory,
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inhibitory control as well as proper planning and execution of behavioral responses to
environmental stimuli. 
The dopamine hypothesis of schizophrenia
The dopamine (DA) hypothesis of schizophrenia in its original form was based
largely on indirect, pharmacological evidence and proposed a hyperactivity of central DA
systems in schizophrenia (see Carlsson 1988). This hypothesis was based on the facts
that all drugs with therapeutic effect on schizophrenia and other psychotic disorders
have antidopaminergic effects, and that amphetamine and related central stimulants,
which directly or indirectly activate brain DA receptors, have been found capable of
eliciting or aggravating psychotic symptoms.
In early studies, Kline (1954) demonstrated for the first time in the Western
world the antipsychotic effects of reserpine. Subsequent experiments by Carlsson and
associates showed that the tranquilizing effect of reserpine is largely due to depletion of
catecholamines such as DA in brain (Carlsson 1965, Carlsson et al. 1967, see Carlsson
1966). Subsequently, Carlsson and Lindqvist (1963) conducted the first study showing
that other antipsychotic drugs, such as chlorpromazine and haloperidol, which displayed
similar behavioral effects as reserpine in experimental animals, act as antagonists at
postsynaptic DA receptors. Carlsson’s initial results and conclusion was later confirmed
by numerous experimental studies in vivo and in vitro utilizing a variety of techniques,
including both functional and biochemical studies in experimental animals, as well as
more recently positron emission tomography (PET) studies in humans in vivo (Andén et
al. 1964, 1966A, Carlsson et al. 1966, Andén et al. 1970, Nybäck & Sedvall 1970,
Aghajanian & Bunney 1973, Seeman & Lee 1975, Creese et al. 1976, Farde et al. 1988).
The classical antipsychotic drugs, such as chlorpromazine and haloperidol, are
generally not equally effective against all symptoms of schizophrenia, i.e. they are most
effective against the positive symptoms. In addition, classical antipsychotic drugs possess
several undesirable properties, for example extrapyramidal side effects (EPS) such as
Parkinsonism, akathisia, acute dystonia and tardive dyskinesia, and they also display a
relatively poor effect against negative symptoms and elicit a motivational deficit
syndrome (see Casey & Keepers 1988, Meltzer 1992). The EPS and the demotivational
action as well as potential worsening of negative symptoms result in relatively poor
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compliance with classical antipsychotic treatment. Thus, mere DA receptor antagonism
has clearly not proven to be a panacea in the treatment of schizophrenia, although it
represents so far the only generally recognized mechanism of action for our presently
used antipsychotic drugs.
The first antipsychotic drug to be developed which in essence does not cause
EPS was clozapine. In contrast to many classical antipsychotic drugs, which in clinically
effective doses show approximately 75% DA-D2 receptor occupancy, clozapine is
effective already at 45-50% DA-D2 receptor occupancy (Farde et al. 1988, Nordström et
al. 1995). Moreover, it frequently exerts a therapeutic action also against negative
symptoms and may be efficacious also in neuroleptic-resistant schizophrenia (Kane et al.
1988, see Meltzer 1995). Since clozapine, in addition to its DA-D2 receptor antagonistic
effects, also possesses relatively high affinity for D1 and D4 receptors and many
neurotransmitter receptors, such as noradrenergic a1-adrenoceptors, serotonin (5-HT)2A ,
5-HT6 and 5-HT7 receptors, muscarinic and histaminergic receptors (see Seeman 1990,
Roth et al. 1998), a crucial, as yet unresolved question is which of these other receptor
affinities that, singly or in combination, contribute to its therapeutic effect.
The second major line of evidence which supports the DA hypothesis of
schizophrenia is also based upon pharmacological data. Thus, high doses of
amphetamine, especially when chronically administered, can induce an acute paranoid
psychosis which in some ways mimics schizophrenia, particularly the positive symptoms
in healthy subjects, and may also exacerbate such symptoms in schizophrenic patients
(see Angrist et al. 1994). These findings are significant as amphetamine potently releases
extravesicular DA (see Carlsson et al. 1967) and causes marked behavioral stimulation,
i.e. hyperlocomotion and stereotyped behavior in rodents, a behavioral syndrome
proposed to represent an animal model of schizophrenia (Randrup & Munkvad 1967).
However, one significant shortcoming of the amphetamine model of schizophrenia is
the fact that the D-amphetamine induced psychosis generally fails to reproduce negative
symptoms. In fact, when D-amphetamine is given to schizophrenic patients negative
symptoms may in some cases even improve (van Kammen and Boronow 1988). This
finding is difficult to reconcile with the DA hypothesis of schizophrenia in its original
form. 
Generally, global DA hyperactivity can not readily account for all symptoms of
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schizophrenia, particularly the negative symptoms. Unequivocal clinical evidence to
substantiate increased activity of DA systems in the brains of schizophrenic patients has
been difficult to obtain. Some clinical studies even indicated a reduction of central DA
output in schizophrenia, specifically in patients with prominent negative symptoms and
marked emotional withdrawal (van Kammen et al. 1986, Karoum et al. 1987).
Interestingly, several early studies showed that these symptoms are associated with a
decreased capacity to functionally activate the dorsolateral prefrontal cortex (Ingvar &
Franzén 1974, Weinberger et al. 1986, Ingvar 1987), a brain region which contributes a
major EAA input to the DA cells in the midbrain. Moreover, dopaminergic activity, in
turn, appears to be one mechanism by which physiological activity of the PFC is
enhanced (cf. Weinberger 1987). Therefore, it was of interest that experimentally
induced, reversible “hypofrontality”, i.e. impaired functional activity in the
corresponding brain region in the rat, i.e the MPFC, produced by local cooling or by
means of local application of lidocaine, was found to cause a nearly total extinction of
phasic, burst activity in VTA DA neurons, although the average firing rate was still not
significantly affected (Svensson & Tung 1989, Murase et al. 1993). In other words, a
pacemaker-like firing of the VTA DA cells was obtained, reminiscent of the firing
pattern of DA neurons observed in the deafferented, midbrain slice preparation. Such a
dysfunction of midbrain DA cells, if also present in man, might contribute to explain the
decreased capacity to process positive or negative reinforcement generally associated
with impaired frontal lobe function and with schizophrenia (Svensson & Tung 1989).
The specific reduction in burst firing caused by experimental hypofrontality could be
significantly antagonized by pretreatment with the 5-HT2A-2C receptor antagonist,
ritanserin or the potent 5-HT2A receptor antagonist amperozide, thus indicating that 5-
HT2A receptor antagonism was critically involved (Svensson et al. 1989, Grenhoff et al.
1990). Other experimental studies showed that ritanserin when given alone caused a
preferential activation of VTA neuronal activity, in particular burst firing, an effect
unrelated to DA-D2 receptor activity in brain (Ugedo et al. 1989). These experimental
findings appeared particularly intriguing since in early clinical studies ritanserin had been
claimed to antagonize dysthymia, as well as to improve drive and motivation and,
importantly, to reduce negative symptoms in schizophrenia (Reyntjens et al. 1986,
Gelders et al. 1986, Duinkerke et al. 1993). Thus, the above results suggested that
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negative symptoms may be a consequence of reduced, and not increased, DA activity in
brain, in particular impaired phasic (dynamic) neuronal activity in VTA DA cells.
Consequently, both preclinical and clinical data are consistent with the notion
that both hyperfunctioning and hypofunctioning DA systems might simultaneously
occur in different brain regions in schizophrenia (cf. Weinberger 1987, Svensson et al.
1993). Such a differential dysfunction of DA systems probably reflects the differential
regulation of DA neuronal subpopulations in the VTA and may be caused by an altered
balance of inputs converging on the DA neurons from different sources in the brain (cf.
Nauta 1976, Svensson et al. 1995). Thus, the DA hypothesis of schizophrenia in its
original form, postulating a global hyperactivity of brain DA systems, appeared less
attractive and, instead, the concept of dysregulation of brain DA neurons as a
pathophysiological substrate for disease symptomatology has evolved. Given the
fundamental role of EAA receptors in the regulation of VTA DA neurons an increased
interest developed in another psychotomimetic compound, namely phencyclidine (PCP),
a potent EAA receptor antagonist. PCP had already in the fifties been found to possess
potent schizophrenomimetic properties (Luby et al. 1959). The newly acquired
knowledge about the EAA receptor mediated regulation of the firing pattern of the
mesocorticolimbic DA neurons in the VTA favored such an experimental approach.
Excitatory Amino Acids
The EAAs glutamate and aspartate are the most abundant of all amino acids in
the brain, and are known to elicit fast excitatory responses in neurons in various species,
from e.g. crayfish to man. The neurotransmitter nature of these amino acids has been a
matter of scrutiny since the 1960s, and it is now widely recognized that glutamate is the
principal neurotransmitter for fast excitatory signalling in brain, and that, in some
instances also aspartate may act in a similar fashion. Although EAA receptors are now
regarded to be almost ubiquitous (Orrego and Villanueva 1993), binding density varies
between brain regions. Glutamate exerts its excitatory actions on neurons via activation
of mainly two principal groups of EAA receptors, ionotropic and metabotropic
receptors. Both groups of EAA receptors are found in the VTA. For reasons of
practicality, only the ionotropic receptors will be discussed here. 
Ionotropic EAA receptors are multi-subunit transmembrane proteins that
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Fig. 5: Schematic drawing of the three major types of ionotropic excitatory amino
acid receptors (Adapted from Kandel et al. 1991). 
consist of a conducting pore embedded in the cell membrane and various binding sites
on the outer, extracellular surface of the receptor (Fig. 5). The ionotropic receptors are 
named after the amino acid analogs to which they respond selectively. The a-amino-3-
hydroxy-5-methyl-isoxazole proprionic acid (AMPA) receptor, formerly known as the
quisqualate receptor, is associated with a cation channel that is nonselective with respect
to Na+ and K+ ions, but impermeable to Ca2+. AMPA receptor mediated currents
exhibit very fast kinetics; with fast onset, offset and desensitization. The AMPA
receptors are widely distributed in the brain, with high density in the hippocampus and
olfactory tubercle (Petralia et al. 1992). This EAA receptor subtype is considered to be a
major mechanism for fast excitatory signalling in the brain (Seeburg 1993). Currently
there are four different subunits described for AMPA receptors termed GluR1 through
GluR4, each of which occurs in two variants, “flip” and “flop” which are the result of
alternative gene splicing. 
Kainate receptors are similar in ion gating and kinetics to AMPA receptors and
may be formed from five subunits designated GluR5, GluR6, GluR7, KA1 and KA2.
(Petralia et al. 1994A). Selective antagonists AMPA or kainate receptor subtypes have
been developed only relatively recently due to the structural similarities between them,
which together were frequently denoted ‘non-NMDA’ EAA receptors. 
The NMDA receptors exhibit comparatively slower kinetics than AMPA and
kainate receptors and also show significant permeability to Ca2+ ions in addition to Na+
and K+. NMDA receptors may be composed of various subunits, e.g. NR1 (which exists
27
in at least nine isoforms) and NR2A-NR2D. The NMDA receptor has a number of
regulatory sites. For example, activation of NMDA receptors by glutamate has been
shown to require concomitant binding of glycine to a specific glycine binding site. In
addition, NMDA receptors are blocked by relatively low concentrations of Mg2+ via
interaction with a binding site within the ion channel complex. The NMDA receptors
are widely distributed in brain, with high densities found in cortical regions and
hippocampus (Petralia et al. 1994B,C).
The phencyclidine model of schizophrenia
Phencyclidine
PCP is an anesthetic agent synthesized in the early 1950s. Clinically PCP was
found to cause a state of “mind-body” dissociation in which the patients were
impervious to pain, yet did not lose consciousness as with the conventional general
anesthetics. Due to several reports describing severe side effects in patients, including
disorientation, agitation, visual and even auditory hallucinations and sometimes violent
behavior, particularly during emergence from PCP anesthesia, PCP was withdrawn from
clinical use in 1965 (see Domino & Luby 1981). 
Subanesthetic doses of PCP reportedly cause symptoms such as apathy, but may
also cause euphoria, a loss of the ability to differentiate between self and non-self,
cognitive disorganization, inability to concentrate or to think abstractly, and in higher
doses catatonic stupor, ataxia and rigidity can occur (see Luby et al. 1959). A number of
clinical studies have reported that PCP not only can cause positive symptoms of
schizophrenia, as seen also in amphetamine induced acute paranoid psychosis, but also
negative symptoms, as well as formal thought disorder and cognitive deficits as
otherwise encountered in schizophrenia. In contrast to almost all other drug induced
psychotic syndromes, auditory hallucinations have also been reported to occur following
PCP administration. Significantly, the PCP induced psychosis can persist for several
weeks in some cases and has been observed even in healthy subjects after administration
of a single dose of the drug (Luby et al. 1959). In addition, when given to schizophrenic
patients, PCP may precipitate psychotic relapse or exacerbate pre-existing psychotic
symptoms. These findings strongly suggest that PCP and schizophrenia may share
common mechanisms in the generation of psychotic symptoms (for review see Domino
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1964, Snyder 1980, Aniline & Pitts 1982, Javitt & Zukin 1991) and, that PCP interferes
specifically with brain neurotransmitter mechanisms of significance to the generation of
psychosis.
Mechanism of action of phencyclidine
PCP interacts with a number of binding sites in brain, e.g. NMDA receptors,
monoamine reuptake carriers, sigma binding sites and a number of other receptors and
ion channels, in order of decreasing affinity. However, when administered in
psychotomimetic doses, PCP acts predominantly as a non-competitive antagonist at the
NMDA subtype of EAA receptors. Other non-competitive NMDA receptor
antagonists, e.g. ketamine and memantine, have also been reported to cause psychotic
symptoms to an extent that is well correlated with their affinity for NMDA receptors
(Fig. 6, Krystal et al. 1994, Lahti et al. 1995, see Kornhuber & Weller 1995). In addition,
several competitive NMDA receptor antagonists have subsequently been associated with
psychotomimetic effects when administered to human subjects (Kristensen et al. 1992,
Clark & Coull 1994, Grotta et al. 1995). Systemic administration of MK-801, the most
specific non-competitive NMDA receptor antagonist to date, was also found to elicit the
typical psychotomimetic effects of PCP in human volunteers, an observation that
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Fig. 6: Correlation between psychotomimetic effect of non-competitive NMDA
receptor antagonists and their affinity for the PCP binding site within the NMDA
receptor ion channel. Compounds in parentheses indicate that their psychotomimetic
effects have only incompletely been characterized (Adapted from Kornhuber & Weller
1995).  
precluded further clinical development of this compound (L. Iversen, personal
communication). In addition, PCP is a relatively potent monoamine reuptake blocker, a
property it shares with cocaine and D-amphetamine, two other psychotomimetic
compounds. However, the doses of PCP required to cause significant monoamine
reuptake blockade are sublethal or lethal in humans, a finding which implies that this
mechanism probably only to a minor extent contributes to the induction of PCP
psychosis. Consequently, the psychotomimetic effects of PCP-like drugs generally
appear to stem from drug induced impairment of NMDA receptor function in brain and
the subsequent consequences thereof (Javitt & Zukin 1991, Kornhuber & Weller 1995).
A hypothesis of decreased glutamatergic function in brain in schizophrenia has
also been proposed based on findings indicating that schizophrenic patients may have
decreased concentrations of glutamate in cerebrospinal fluid (Kim et al. 1980). In
addition, in post-mortem brains both glutamate uptake and kainate receptor binding
may be increased in the PFC in schizophrenics, a finding which was interpreted to
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indicate an impaired glutamatergic neurotransmission (Nishikawa et al. 1983, Deakin et
al. 1989). Such results, in addition to the findings with the PCP model of schizophrenia,
contributed to support the glutamate hypothesis of schizophrenia (see Kim et al. 1980).
In essence, this hypothesis postulates that reduced activation of the NMDA subtype of
glutamate receptor or a hypoglutamatergic state in brain might play a pivotal role in the
generation of psychotic symptoms (for review see Bunney et al. 1995).
Pharmacological properties of non-competitive NMDA receptor antagonists
PCP binds to a specific binding site within the NMDA receptor ion channel
complex, similarly to the selective ligand dizocilpine (MK-801) which, however, is
approximately 10-fold more potent than PCP (Fig. 6). Thus, PCP displaces [3H]-MK-801
binding in brain slices with a potency well correlated to its antagonistic action at NMDA
receptors (Anis et al. 1983, Wong et al. 1986). This antagonistic effect appears to be both
use- and state-dependent; it requires the NMDA receptor ion channel to be open and
the voltage-dependent Mg2+ blockade of channel opening to be overcome by membrane
depolarization to allow the antagonist to reach its binding site. Similar ligands such as
PCP, ketamine and MK-801 bind rapidly but dissociate slowly from the ion channel
complex (Wong et al. 1986, Lodge et al. 1987, Lodge & Johnson 1990, Wong & Kemp
1991). When administered systemically to rodents, MK-801 rapidly enters the brain,
attaining maximal concentrations within ten minutes of injection, and its plasma half-life
is approximately two hours (Hucker et al. 1983). Furthermore, MK-801 generalizes to
PCP in discriminative stimulus tests and vice versa (Tricklebank et al. 1987, 1989). 
Systemic administration of non-competitive NMDA receptor antagonists,
including PCP and MK-801, causes a behavioral syndrome in rodents characterized by
e.g. increased horizontal locomotor activity with frequent turning. Also, a stereotyped
behavioral repertoire is observed, especially with high doses, including pronounced head
weaving (repetitive side-to-side, left-to-right swaying movements of the head and upper
torso) and sniffing. When higher doses are administered (i.e.>0.3 mg/kg to rats),
increasing ataxia is obtained, an effect characterized by tottering of the hindquarters,
abduction and dragging of hindlimbs, flat body posture, and loss of balance
(Clineschmidt et al. 1982, Lehmann-Masten & Geyer 1991, Bubser et al. 1992, Löscher
& Hönack 1992). Recent studies have shown that non-competitive NMDA receptor
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antagonists also cause deficits in prepulse inhibition as assessed by acoustic startle
response (see Zhang et al. 1997). PCP-like drugs have also been shown to impair social
interaction in rodents (Steinpreis et al. 1994). Retention of new information and learning
are impaired under the influence of PCP-like drugs (Wozniak et al. 1990). In view of
these effects, it seems reasonable to assume that the PCP model of schizophrenia
currently represents the most accurate, pharmacologically induced behavioral model of
the disease. A major question remained, namely to what extent this model is compatible
with, or relate to, the DA hypothesis of schizophrenia, an issue which will be briefly
discussed below.
Involvement of DA in behaviors induced by NMDA receptor antagonists
Several early studies reported an increase in VTA DA cell firing rate following
systemic administration of low doses of PCP (Freeman & Bunney 1984, French 1986).
However, administration of high doses, i.e >2 mg/kg intravenously, was associated with
a decrease in firing rate, an effect which was attributed to the DA reuptake blocking
effect of the drug. Subsequent studies of other non-competitive NMDA receptor
antagonists revealed a stimulating effect on firing rates of midbrain DA neurons similar
to that of PCP (Freeman & Ceci 1990). However, the questions about the effects of
PCP-like drugs on the physiological regulation of the firing patterns and dynamic
response range of the mesocorticolimbic DA neurons remained to be elucidated. A PCP
induced increase in DA metabolism was also observed and found to be associated with
locomotor hyperactivity, an effect that could be blocked by 6-hydroxydopamine lesions
of the VTA (French et al. 1985). The hyperlocomotion induced in rodents by
systemically administered NMDA receptor antagonists in relatively low doses could also
be abolished by depletion of DA from neuronal stores by pretreatment with reserpine
and/or a-methyl-p-tyrosine (Fessler et al. 1980, Clineschmidt et al. 1982), or attenuated
by systemic administration of DA receptor antagonists (Murray & Horita 1979,
Clineschmidt et al. 1982). These observations  indicate that brain DA systems are
critically involved in the mediation of behavioral effects induced by PCP and MK-801 in
low, non-ataxic doses. Later studies reported that high doses of MK-801, i.e. >1 mg/kg,
could also induce locomotor hyperactivity in monamine-depleted mice (Carlsson &
Carlsson 1989). However, such high doses were reported to be associated with profound
32
ataxia in rats (Criswell et al. 1993). These findings indicate a contribution also of DA-
independent mechanisms to the locomotor hyperactivity induced by very high doses of
MK-801.  However, questions as regards the putative effects of PCP-like drugs on DA
release in different nerve terminal regions, such as the cortical and subcortical
projections of the VTA, remained elusive. In addition, the relationship between drug
induced changes in electrophysiological activity of the DA neurons and transmitter
release remained to be investigated. Since the psychotomimetic actions of PCP-like
drugs basically seem to be related to NMDA receptor antagonism this analysis was
especially focussed on the central actions of systemically administered MK-801, the most
specific of the non-competitive NMDA receptor antagonists.
Consequently, the precise way in which PCP-like drugs affect the function of
mesolimbic and mesocortical DA neurons appeared to be of major scientific interest,
since insights gained within this framework might aid in the conceptualization of the
emergence of psychotic pathophysiology. A second rationale for our work was that such
insights might also be used to facilitate development of novel pharmacological strategies
to treat psychoses. The present work was directed towards these two ends.
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Specific aims
- To study the effects of acute administration of non-competitive NMDA receptor
antagonists on 
- (I) The firing patterns of mesolimbic and mesocortical DA neurons. 
- (II) Regional release of DA and NT in mesolimbic (VSTR) and mesocortical
(MPFC) DA terminal regions.
- To study the precise mechanisms underlying the effects of systemically administered
non-competitive NMDA receptor antagonists on the mesocorticolimbic DA systems,
i.e.
- (III) The significance of nerve impulse activity in the DA neurons for basal and
evoked DA release in the NAC and MPFC.
- (IV) The significance of AMPA and/or kainate receptors in the VTA for basal
and MK-801 evoked DA release in the NAC and locomotor stimulation.
- (V) To study the tentative antagonistic action of a1-adrenoceptor blockade on MK-801
evoked DA release in the NAC and locomotor stimulation.
- (VI) To study the effects of AMPA receptor antagonists on the conditioned avoidance
response and catalepsy score.
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Materials and Methods
Animals and general experimental protocols
Male albino rats (Bantin and Kingman Universal AB, Sollentuna, Sweden)
weighing between 250-350 g were used. BKl:WR (i.e. Wistar) rats were used in
microdialysis and locomotor activity studies, and BKl:SD (i.e. Sprague-Dawley) rats were
used in electrophysiological, conditioned avoidance and catalepsy experiments. Animals
arrived at least one week before use and were housed five per cage under standard
laboratory conditions, maintained on a 12 h light:dark cycle with lights on at 06:00,
except for conditioned avoidance and catalepsy experiments where a reversed light:dark
cycle was used, i.e. lights on at 18:00. Animals had access to R34 rat chow and water ad
libitum. Only experimentally naive rats were used. All experiments were conducted with
the permission and in accordance with the guidelines of the local ethical committees
(Stockholms Norra och Södra Försöksdjursetiska Kommittéer).
Drugs
Phencyclidine hydrochloride (PCP; a generous gift from Astra Arcus AB),
dizocilpine maleate (MK-801; (+)-5-methyl-10,11-dihydroxy-5H-dibenzo-
(a,d)cyclohepten-5,10-imine maleate; Research Biochemicals Inc.), and D-amphetamine
(Sigma) were dissolved in 0.9% saline solution for systemic injection. Prazosin (1-(4-
amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine; Pfizer AB), an a1-
adrenoceptor antagonist, was dissolved in a drop of glacial acetic acid and titrated to
volume using 5.5% glucose solution for systemic administration. LY326325 ( LY293558
monohydrate; [3S(3a,4aa,6ß,8aa)]decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]3-
isoquinolinecarboxylic acid monohydrate; a generous gift from Eli Lilly and Company),
an AMPA receptor antagonist, was dissolved in distilled water. CNQX (6-cyano-7-
nitroquinoxaline-2,3-dione; Research Biochemicals Inc.), an AMPA and kainate receptor
antagonist, was dissolved to a concentration of 100 mM in pure dimethylsulfoxide
(DMSO). Immediately before use, this CNQX stock was diluted with perfusion solution
(147 mM sodium chloride, 3.0 mM potassium chloride, 1.3 mM calcium chloride, 1.0
mM magnesium chloride, and 1.0 mM sodium phosphate, pH 7.4) to 0.3 and 1 mM for
local perfusion via a microdialysis probe. Tetrodotoxin (TTX; Research Biochemicals
Inc.), a sodium channel blocker which inhibits action potential generation, was dissolved
in perfusion solution to a concentration of 1 µM for local perfusion via a microdialysis
probe. Sodium pentobarbital was purchased as a solution, ready for systemic injection
(Apoteksbolaget, Umeå). Chloral hydrate (Merck) was dissolved in 0.9% saline solution
for systemic injection.
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Extracellular single cell recording
Surgery and experimental procedures
The electrophysiological experiments followed the general procedures routinely
used in this laboratory since more than a decade (see Grenhoff et al. 1986, Murase et al.
1993). Rats in studies I and II were anesthetized with chloral hydrate (400 mg/kg, i.p.)
and maintained under surgical anesthesia throughout the experiments. A tracheal
cannula and a jugular vein catheter for i.v. drug administration were inserted. The animal
was subsequently mounted in a stereotaxic apparatus (David Kopf). Body temperature
was kept at 37E C by means of a thermostatically controlled heating pad. A hole was
drilled overlying the VTA, i.e. 3.0 mm anterior and 0.7 mm lateral to lambda (Paxinos
and Watson 1986), and the dura mater was removed. At the end of each experiment a
negative current of 5 µA was passed through the electrode for 10 min to mark the
recording site (Lodge et al. 1974). Subsequently, rats were killed by overdose of
anesthesia, brains were removed and stored in 25% sucrose in 10% formaldehyde. The
brains were finally sliced in 50 µm thick sections and stained with neutral red. All
recording sites included in these studies were confirmed under microscope to be
correctly located within the VTA or the SN-ZC. In addition, anatomical localization of
recording sites within subnuclei of the VTA were made in accordance with the atlas of
Paxinos and Watson (1986) by three independent observers who were blind to the
obtained effect on the recorded cell.
Extracellular recordings
Recording electrodes were pulled from Omegadot glass capillaries in a vertical
electrode puller (Narshige) and filled with 2M sodium acetate saturated with Pontamine
Sky Blue. The tips were broken back under microscope to an impedance of 2.0-3.0 MO
measured at 135 Hz. Electrodes were lowered into the brain by means of a hydraulic
microdrive (David Kopf). A reference electrode was also inserted into the subcutaneous
tissue. The signal was amplified and visualized on a digital oscilloscope (Tektronix TDS
310) connected to an IBM compatible computer which allowed screen captures from
the oscilloscope. Spikes were discriminated from background by means of a window
discriminator. Subsequently, discriminated spikes were fed via a CED 1401 interface
(Cambridge Electronic Design Ltd.) to a second computer running Spike2 software.
Identification of dopamine neurons and data analysis
Presumed DA neurons were found 7.5 - 8.5 mm from the brain surface and
were recognized by their characteristic triphasic action potential waveforms of more
than 2.0 ms duration, basal firing rates of 1 - 10 Hz and frequent occurrence of burst
firing (Wang et al. 1981). The firing pattern was analyzed for average firing rate,
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percentage of action potentials fired in bursts and variation coefficient, parameters
which were calculated over a period of 500 consecutive inter-spike time intervals,
utilizing an analysis script developed in our laboratory by the author. Average firing rate
was calculated as the ratio between the number of spikes and the time elapsed, expressed
in spikes per second (Hz). The onset of a burst was defined as an interval of less than 80
ms, burst termination as the next interspike time interval exceeding 160 ms (Grace &
Bunney 1984), bursts exceeding 18 spikes were ignored. Burst firing was quantified as the
percentage ratio of spikes in bursts and the total number of spikes. Variation coefficient
was defined as the percentage ratio between the standard deviation and the mean of the
inter-spike time intervals (Werner and Mountcastle 1963). Intravenous drug injections
were administered 3 - 5 min apart. Only one DA cell was studied in each animal.
Statistical analysis
Electrophysiological data were presented as means ± standard error of the mean
(S.E.M.) with the exception of burst firing values which are presented as means only,
since they deviate from a normal distribution. Five hundred intervals preceding the first
drug injection and five hundred intervals after each injection were used for calculation of
control values and drug-induced changes, respectively. For statistical evaluation, firing
rate and variation coefficient values were analyzed by Student’s paired T-test, whereas
burst firing values were analyzed with Wilcoxon’s matched-pairs signed ranks test.
Comparisons of burst firing values between groups were made with the Mann-Whitney
U-test. Comparison of anatomical localization within the VTA was made with Fisher’s
exact test. P values <0.05 were considered significant.
Microdialysis in freely moving rats
Surgery and microdialysis
Rats in study III-VI were anesthetized with sodium pentobarbital (60 mg/kg,
i.p.) and mounted in a stereotaxic frame (David Kopf). Body temperature was
maintained at 37E C with a thermostatically controlled heating pad. Vertical probes of
concentric type were stereotaxically implanted into the VSTR, i.e. AP +1.6 mm, ML -1.3
mm, DV -8.5 mm, the NAC, i.e. AP + 1.6 mm, ML - 1.4 mm, DV -8.2 mm, or the
MPFC, i.e. AP +3.2 mm, ML -0.6 mm, DV -5.2 mm, relative to bregma. In some
experiments, a second microdialysis probe was implanted into the ipsilateral VTA, i.e AP
+3.8 mm, ML -0.5, DV -8.6 mm relative to lambda. Dialysis occurred through a
semipermeable membrane (copolymer of acrylonitrile and sodium methallyl sulfonate,
i.d. = 0.24 mm, 40,000 Da molecular weight cutoff, AN69 Hospal) with an active surface
length of 1.0, 2.25, 3 and 4 mm for VTA, NAC, VSTR and MPFC, respectively.
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After surgery, the animals were housed individually in plexiglass cages (32 x 35 x
50 cm) and given ad libitum access to food and water. All experiments were conducted
approximately 48 h after surgery in awake, freely moving animals during the light cycle.
All drug administrations were carried out after stable baseline conditions were achieved
(<10% variation).
Microdialysis was performed using automated on-line sampling (Nomikos et al.
1989; Nomikos et al. 1994). The dialysis probe was perfused with a physiological
perfusion solution (147 mM sodium chloride, 3.0 mM potassium chloride, 1.3 mM
calcium chloride, 1.0 mM magnesium chloride, and 1.0 mM sodium phosphate, pH 7.4) 
at a rate of either 2.5 or 5 µl/min set by a microinfusion pump (Harvard Apparatus).
The perfusate was loaded directly into the sample loop of the injector (Valco). An IBM
compatible computer controlled the loading and injection modes of the injector.
Samples were automatically injected into the analytical system every 20 min for NAC
samples in studies 4-6, every 30 min for VSTR in study 3 and MPFC in studies 3 and 6
for analysis of DA and its metabolites. Samples designated for NT assay were collected
every 60 min and frozen at -20E C and analyzed within one month. Upon completion of
the experiments, rats were killed by an overdose of sodium pentobarbital and the brains
were removed and stored in 25% sucrose in 10% formaldehyde. Each brain was
sectioned on a microtome (50 µm), stained with neutral red, and examined for probe
placement. Only rats with probes verified to be located within the correct region(s),
according to the anatomical atlas of Paxinos and Watson (1986), were included in these
studies.
Biochemical assays
Concentrations of DA, DOPAC and HVA were determined by high
performance liquid chromatography with electrochemical detection (HPLC-ED) as
previously described by Nomikos et al. (1989). Separation of DA and its metabolites was
achieved by reverse phase chromatography  (column: 150 x 4.6 mm, Nucleosil 5 µm,
C18) with a mobile phase consisting of 0.055 M sodium acetate with 0.1 mM
octanesulfonic acid, 0.01 mM Na2EDTA, and 5% methanol, pH 3.8, adjusted with glacial
acetic acid. The mobile phase was delivered by an HPLC pump (LKB; 2150) at 0.8
ml/min. Before entering the detector, the analysate was passed through a guard cell with
an oxidizing potential of 50 mV. Electrochemical detection was accomplished using a
coulometric detector (Coulochem II model 5200; ESA) with a high sensitivity analytical
cell (5011) in which amine detection was achieved by the sequential oxidation and
reduction of the eluent (coulometric electrode=+0.4 V; amperometric electrode=-0.2
V). Chromatograms were generated by a two-pen chart recorder (Kipp & Zonen) and
simultaneously recorded and analyzed by an IBM compatible computer (Turbochrom
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software; Perkin Elmer). The limit of detection was 1 fmol for DA and DOPAC and 3
fmol for HVA.
Neurotensin-like immunoreactivity (NT-LI) in the dialysates were quantified in
study III by radioimmunoassay (RIA). Standards (140 µl, 1.95 - 125 pmol/l, Peninsula
Laboratories, prepared in the same buffer as perfusion solution) and samples were
incubated at 4E C for 48 hours with 25 µl of NT-antiserum (Cambridge Research
Biochemicals) diluted to give approximately 30% total binding. Following this
incubation, 25 µl of 125I-NT (approximately 3500 cpm; Amersham) was added. After an
additional 24 h at 4E C the bound and free antigen were separated by addition of 50 µl
donkey anti-rabbit antibody-coated cellulose suspension (Sac-Cel; Wellcome
Diagnostics) followed by centrifugation. The antibody is directed against the -COOH
terminal of NT and its specificity is: NT1-13 1.00, NT7-13 0.83, NT1-8 and NT1-9 <0.001.
Using high performance liquid chromatography, it has previously been shown that
antibodies with immunoreactive characteristics similar to these we used recognize
authentic NT from rat brain dialysates (Bean et al. 1989A). The intra- and interassay
coefficient of variance for 3.7 pmol/l were 8 and 11%, respectively. The limit of RIA
detection was 0.05 fmol.
Statistical analysis
For graphical representation of microdialysis data, the average of four baseline
samples immediately preceding drug injection was defined as 100%. All subsequent
measurements were transformed to a mean percentage of baseline values for each
subsequent sampling period. Statistical evaluation was performed using the Statistica
software suite (StatSoft Inc.). For evaluation of changes in dialysate levels of the various
compounds, a one- and two-way (treatment x time) analysis of variance (ANOVA) with
repeated measures was used, followed by the post-hoc Newman-Keuls test for multiple
comparisons. In all statistical tests, a P value <0.05 was considered significant.
Behavioral studies
Locomotor activity
Locomotor activity in studies III and IV was assessed by means of computer-
monitored photocell-equipped boxes (see Ericson et al. 1991). Each animal was placed
in a square plexiglass open-field arena (68 x 68 x 45 cm) within a sound-attenuated and
fan ventilated box, which was kept dark during the duration of the testing session. Two
rows of photocells lined the exterior of the arena. All photobeam interruptions were
recorded and stored on disk by an IBM-compatible computer. Computer recordings of
horizontal activity (lower row interruptions) and rearing (upper row interruptions) were
taken. In study III, peripheral activity (photobeam interruption adjacent to any wall of
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the arena) and forward locomotion (successive interruptions of photobeams when the
animal is moving in the same direction) were also assessed. 
On the day of the experiment, rats were brought to the behavioral testing room
in their home cages and allowed to become accustomed to the new environment for at
least 60 min. Rats received drugs systemically and were immediately placed in the
locomotor activity boxes. The interior of the locomotor activity boxes was wiped clean
after each session. All behavioral monitoring was conducted during the light cycle
between 08:30 and 17:00. 
Visual assessment of MK-801 evoked behaviors
In study V, behavioral assessment was carried out simultaneously with ongoing
microdialysis experiments (cf. above); thus, the behavior of the above animals was
continuously observed to ascertain any overt changes. Characteristic MK-801 induced
behaviors (Clineschmidt et al. 1982, Löscher & Hönack 1992) were rated by two
independent observers, and were measured by the time during which the rats exhibited
the following behaviors: Locomotor activity, ipsi- and contralateral turning, sniffing,
head weaving and ataxia. Head weaving was determined as repetitive side-to-side, left-to-
right swaying movements of the head and upper torso. Ataxia was defined as tottering
of the hindquarters, abduction and dragging of hindlimbs, flat body posture, and loss of
balance  (Löscher & Hönack 1992). All behavioral monitoring was conducted during the
light phase of the daily cycle between 12:00 and 17:00.
Conditioned avoidance response
In study VII, a shuttle-box (530 x 250 x 225 mm) divided into two
compartments by a partition was used (see Wadenberg et al. 1990). Upon presentation
of a conditioned stimulus (CS; 80 dB white noise) the animals had 10 s to move into the
adjacent compartment of the shuttle-box. If the rat remained in the same compartment
for longer than 10 s, the unconditioned stimulus (UCS) was presented, i.e. an
intermittent electric shock in the floor grid (4 shocks per 10 s,  duration 0.5 s,
approximately 0.2 mA), until an escape response was performed, i.e. moving into the
other compartment. Avoidance was recorded as a response to the CS within 10 s, escape 
as response to CS and UCS, i.e. > 10 s, and intertrial crosses, i.e. movement between
compartments between trials. The animals were trained for three consecutive days and
were initially habituated to the shuttle-box for 5 min, and subsequently trained. Each
training session consisted of 20 trials randomly distributed over 15 min.  
Experimental trials were preceded by a pre-test to reaffirm the rats' maintenance
of CS responding ($80% avoidance). All pre-tests and experimental trials consisted of 10
trials randomly distributed over 7.5 min. Test sessions were conducted 20, 90 and 240
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minutes after systemic administration of drug or vehicle. Animals were subjected to
repeated observations using a cross-over design (Li, 1964) with a one week inter-trial
delay period.
Catalepsy
Animals were placed on an 60E inclined grid in study VII and, excluding the first
30 s, the time the rat remained in the same position was measured, for a maximum of
2.5 min. The catalepsy was scored from 0-5 according to the (square root
transformation) immobility time (min): 0 = 0-0.08, 1 = 0.09-0.35, 2 = 0.36-0.80, 3 =
0.81-1.42, 4 = 1.43-2.24, 5 $ 2.25.
Statistical analysis
Photocell measurements of behavior are presented as means ± S.E.M. of raw
values of behavioral parameters over time. Data were analyzed by a two-way ANOVA,
followed by LSD test in paper III or the Neuman-Keuls test for multiple comparisons in
paper IV.
Visual assessments of behaviors are presented as mean ± S.E.M. times the
animals displayed the various behaviors. Data were analyzed using one-way ANOVA and
the post-hoc Neuman-Keuls test.
In the CAR experiments, avoidance data are presented as medians ± semi-
interquartile range. CAR data and intertrial crosses were analyzed using the Friedman's
analysis of variance (ANOVA) followed by the Wilcoxon's signed ranks test. Catalepsy
scores were statistically analyzed using the Kruskal-Wallis ANOVA followed by the
Mann-Whitney U-test (Ahlenius and Hillegaart 1986). P values < 0.05 were considered
significant.
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Results and Discussion 
I: Effects of PCP and dizocilpine (MK-801) on the firing pattern of midbrain dopamine neurons
(Papers I & II)
In an initial study we characterized the effects of a single, relatively low systemic
dose of PCP (1 mg/kg, i.v.) on the firing pattern of VTA DA neurons, utilizing
extracellular single cell recording techniques. While this dose of PCP elevated the average
firing rate of VTA DA cells, in agreement with the previous results (Freeman & Bunney
1984, French 1986), it also caused differential effects on the firing pattern of VTA DA
neurons. Thus, DA cells which initially displayed a bursty firing pattern responded to
PCP administration by a regularization of the firing pattern and a reduction in burst
firing. In contrast, DA neurons displaying relatively little burst firing before PCP
administration responded with an increase in the variation coefficient (deregularization)
and an increase in the percentage of spikes in bursts, as defined by the computer
program used at this time(Grenhoff et al. 1988A). Thus, the overall VTA DA cell
discharge was increased, yet abnormal as regards its temporal distribution. Other
previous experiments had indicated that the VTA DA cell firing pattern is a major
determinant of normal reward motivated behavior (Schultz et al. 1986, Nishino et al.
1987) as well as DA release from DA neurons (Gonon 1988). These conclusions have
been supported by many subsequent studies (see Bunney 1992, Murase et al. 1993,
Suaud-Chagny et al. 1992, Chergui et al. 1993, Schultz et al. 1993, Chergui et al. 1996,
Schultz 1998). Consequently, we hypothesized that the abnormal functioning of
subgroups of VTA DA neurons induced by PCP might contribute to the generation of
abnormal behaviors, e.g. psychotic symptomatology.
 PCP had been reported to reduce VTA DA cell firing rate in rats when doses
>2.0 mg/kg i.v. were used, a finding that might reflect the dopamine reuptake blocking
effect of PCP (Freeman & Bunney 1984, French 1986, Zhang et al. 1992). We therefore
chose to subsequently investigate the actions on midbrain DA cell firing patterns of the
more selective non-competitive NMDA receptor antagonist MK-801, which displays
approximately 10 times more potent binding to the PCP site within the NMDA receptor
ion channel than PCP, but lacks reuptake inhibitory properties.
Systemic administration of MK-801 (0.01-1 mg/kg, i.v.) caused a significant and 
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dose dependent increase in the average firing rate of DA neurons in both the VTA and
the SN-ZC, in similarity to previous findings with PCP and MK-801 (Freeman &
Bunney 1984, French 1986, French & Ceci 1990). In addition, we demonstrated that
systemic MK-801 also significantly decreased the variability of DA cell impulse activity in
a dose-dependent manner, as assessed by the variation coefficient, in both VTA DA and
SN-ZC cells. Previous studies indicate that the dynamic response range, or variability, of
neuronal activity is a necessary and adaptive feature of neuronal systems, in particularly
within the context of learning or adaptation to novel situations (Servan-Schreiber et al.
1990). Thus, the reduced variability of firing of midbrain DA neurons caused by
systemically administered psychotomimetic NMDA receptor antagonists may per se
imply a generally reduced adaptive capacity of midbrain DA neurons to respond
adequately to environmental demands. In SN-ZC cells, a modest yet significant increase
in burst firing was obtained. Moreover, different VTA DA cell groups responded to
MK-801 in a differential manner with respect to burst firing, in similarity to our previous
findings with PCP. These effects were significant and also dose-dependent, indicating
that they were, indeed, drug induced. Thus, in one group of VTA DA neurons, a marked
decrease in burst firing was obtained (Fig. 7), in similarity to the previously observed
effect of the broad-spectrum EAA receptor antagonist, kynurenate (Grehoff et al.
1988B). In contrast, in a second group of VTA DA neurons, several cells were activated
by MK-801 to such an extent that they were interpreted by the computer as being
essentially continuously bursting (Fig. 8). Thus, the average inter-spike interval often was
shorter than 160 ms,theminimum interval required to signal burst termination in DA
cells, due to the large increase in firing rate following MK-801 administration. Since this
firing pattern was essentially devoid of post-burst pauses in DA cell activity and
displayed a low variation coefficient, this firing pattern will henceforth be referred to as
‘burst-like’, even though it formally meets the previously established criteria for burst
firing proposed by Grace & Bunney (1984).
Post mortem histological inspection revealed the following picture: Cells which
displayed a high frequency, burst-like firing pattern after MK-801 administration were
preferentially located within the paranigral (PN) subdivision of the VTA, that projects to
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Fig. 7: Effects of systemic administration of MK-801 on the firing pattern of a
VTA DA cell in the PBP, as shown by sequential interspike time interval
histograms (ISH:es), burst firing illustrated by black bars (upper panel), and
ratemeter recording (lower panel). Drug injections indicated at arrows. MK-801
administration caused only a minor increase in the average firing rate, whereas the
firing pattern was clearly regularized, as shown by a gathering of the ISH around
the mean interspike time interval (ISHc). Burst firing decreased in a dose-
dependent manner, and was abolished following administration of the final dose
of MK-801 (ISHc, 0.4 mg/kg, i.v.).
subcortical areas, which are involved in motor function and reward related behaviors, i.e.
caudate-putamen, NAC and septum (cf. introduction). In contrast, VTA DA neurons
that responded to MK-801 with a decreased burst firing were instead mainly localized
within the parabrachial pigmented (PBP) subdivision of the VTA, an area which
essentially provides the DA innervation of the PFC. Statistical evaluation revealed that in
response to MK-801 administration cells localized in the PN, analyzed as a group,
displayed significantly augmented burst-like firing, whereas PBP neurons displayed a
significant decrease in the percentage of bursts. We subsequently reinvestigated the
histological localization of the recording sites from our previous study on PCP and the
above described pattern of distribution was also found in cells responding differentially
to PCP (unpublished observations). Consequently, relatively low doses of both MK-801
and PCP potently activate burst-like firing in subcortically projecting, mesolimbic DA 
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Fig. 8: Effects of systemic administration of MK-801 on the firing pattern of a
VTA DA cell in the PN, as shown by sequential interspike time interval hisograms
(ISH:es), burst firing illustrated by black bars (upper panel), and ratemeter
recording (lower panel). Drug injections indicated at arrows. MK-801
administration caused an increase in average firing rate and a regularization of
firing, as shown by a gathering of the ISH around the mean interspike time interval
(ISHc). MK-801 administration evoked a high frequency burst-like firing pattern
(ISHc).
neurons, while both drugs concomitantly attenuate burst firing in DA cells, which 
largely, but not exclusively project to the prefrontal cortical region.
The increased firing rate in DA cells observed following administration of low
doses of PCP must thus be related related, albeit indirectly, to the non-competitive
NMDA receptor antagonistic properties of this drug since MK-801 produced the same
effect. The reduced burst firing observed in VTA DA cells in the PBP is very likely a
direct consequence of NMDA receptor antagonism of DA cells, since local application
of NMDA receptor antagonists to the VTA DA neurons has been shown to specifically
attenuate the burst firing mode (Chergui et al. 1993, Tong et al. 1996). However, the
pronounced increase in firing rate and burst-like firing pattern found in VTA DA cells in
the PN following systemic administration of PCP or MK-801 could not readily be
explained by such a mechanism. Tentative mechanisms might instead involve a
decreased GABAergic inhibition of the DA cells (Zhang et al. 1993), or an enhanced
activation of the DA neurons by other, non-NMDA EAA receptors (cf. introduction),
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or both, a question that we subsequently addressed in other studies (see section IV).
Interestingly, PBP and PN neurons have been reported to differ with respect to their
expression of co-existing peptides. In particular, NT seems to be localized to DA
neurons in the PBP rather than those in the PN (Jayaraman et al. 1990, Bayer et al.
1991). Thus, administration of PCP might cause differences in regional DA and NT
release in cortical versus subcortical DA projection areas, a question we also addressed in
subsequent experiments (see section II). In conclusion, the marked burst-like activation
of DA neurons projecting subcortically to brain regions involved in motivational control
and the concomitantly decreased burst firing in DA neurons which project to the PFC, a
region which is involved in cognition and planning of behavior, might infer a possible
basis for the dissociation of cognitive and motivational functions frequently described
following systemic administration of PCP-like drugs (see Luby et al. 1959, Javitt & Zukin
1991). 
II: Effects of PCP on regional release of dopamine and neurotensin in the ventral striatum and the
medial prefrontal cortex and on locomotor activity: comparison with D-amphetamine (Paper III)
Several studies had emphasized the importance of the pattern of monoaminergic
neuronal activity, specifically burst firing, rather than the average rate of discharge for
the release of DA and NT from nerve terminals (see introduction; Gonon 1989, Bean
and Roth 1991). Thus, the above electrophysiological data suggested that non-
competitive NMDA receptor antagonists might differentially affect DA and/or NT-LI
output in cortical and limbic DA terminal regions (see section I). Therefore, we
subsequently studied the effects of systemic PCP and D-amphetamine on extracellular
DA levels in the VSTR and MPFC, using microdialysis in freely moving rats coupled on
line to a HPLC-ED system. In separate animals we also analyzed the PCP and D-
amphetamine evoked changes in dialysate concentrations of NT-LI in the same regions
with RIA. 
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Fig. 9: Effects of systemic PCP and D-amphetamine administration on dialysate
concentrations of DA in the VSTR (A) and the MPFC (B). Arrowheads indicate
drug injection. 
Systemic D-amphetamine administration (1.5 mg/kg, s.c.) caused a pronounced
increase in DA concentrations from the VSTR and the MPFC (Fig. 9). The maximal
increase occurred within 60 min of injection, and was of comparatively larger magnitude
than that observed for PCP, in both regions. The increases in DA concentrations
evoked by D-amphetamine were long lasting; DA levels remained significantly elevated 
for 210 and 180 min in VSTR and MPFC, respectively. In addition, D-amphetamine
administration significantly increased NT-LI levels in MPFC dialysates during the first
one hour sample, but did not affect NT-LI in VSTR dialysates (Fig. 10).
Similarly, PCP administration (2.5 mg/kg, s.c.) also significantly elevated DA
levels in both VSTR and MPFC dialysates (Fig. 9). Thus, in the VSTR, the maximal
increase was achieved at 150 min after PCP injection. In the MPFC, DA levels were also
significantly increased by systemic PCP, reaching a maximal effect sooner than the
increase observed in the VSTR, i.e. 90 min after administration. In parallel to the effects
on DA, NT-LI levels in the first one hour sampling period in both MPFC and VSTR
dialysates were also significantly increased by PCP (Fig. 10).
Animals treated with D-amphetamine showed significant and long-lasting
increases in all behavioral parameters measured, including total horizontal activity,
forward locomotion, peripheral activity and rearing. D-amphetamine decreased the 
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Fig. 10: Effects of systemic PCP and D-amphetamine administration on dialysate
concentrations of NT-LI in the VSTR (A) and the MPFC (B). Arrowheads
indicate drug injection. 
percentage of peripheral activity as a ratio of total horizontal activity, which indicates a
decrease in thigmotactic scanning, i.e. a common mode of exploratory locomotion in
many species of mammals, including rats. In addition, D-amphetamine caused an
increase in forward locomotion when expressed as a percentage of total horizontal
activity, i.e. an increase in the perseverance of linear movement. 
Similarly to D-amphetamine, PCP administration increased several parameters of
locomotor activity, i.e. total horizontal activity and peripheral activity. However, the PCP
induced behavioral activation was of smaller magnitude. In fact, during the first 30 min
measurement period, PCP administration even decreased rearing. PCP also decreased
the percentage ratio of peripheral activity to total horizontal activity and increased the
ratio of forward locomotion to total horizontal activity.
In summary, these experiments show that D-amphetamine and PCP enhance
DA output in the VSTR and MPFC in a similar manner, evoke marked behavioral
stimulation and also alter the pattern of locomotor activity. The D-amphetamine and
PCP evoked changes in the pattern of locomotor activity were temporally associated
with the changes in DA output. However, although the effects of these two compounds
on NT-LI levels in the MPFC were similar, only PCP elevated NT-LI levels in the
VSTR. In view of the inhibitory effect of NT on DA receptor evoked responses in the
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VSTR the temporal association of increases in NT-LI in the VSTR and the generally
poor locomotor stimulation and reduced rearing following PCP administration, a causal
relationship between these effects of PCP is suggested. Since several studies indicate that
release of coexisting peptides as well as DA might be particularly effective during burst
activation of monoamine containing neurons, the relatively large increase in release of
both DA and NT in the MPFC following PCP administration may seem surprising since
PCP administration decreased burst firing in cortically projecting VTA DA cells (see
section I). These results might indicate that the PCP induced release of both DA and
NT in the MPFC to a significant extent is independent of changes in nerve impulses, a
hypothesis that we subsequently decided to investigate (see below, section III).
III: Significance of nerve impulse activity in the ventral tegmental area for basal and MK-801 evoked
dopamine release in the nucleus accumbens and medial prefrontal cortex (Paper VI)
We had previously shown that systemic PCP and MK-801 cause reduced burst
firing in VTA DA neurons in the PBP, which provides the DA projection to the MPFC.
Yet, several subsequent microdialysis studies reported a marked increase in DA output in
this region following systemic administration of these drugs (see section II, Wdzony et
al. 1993, Wolf et al. 1993). These findings raised the possibility that PCP-like drugs evoke
DA release in the MPFC largely via a mechanism independent of DA neuronal activity,
i.e. it could be locally elicited in the DA nerve terminal region within the MPFC (see
section II). Therefore, we studied the importance of nerve impulse activity in the VTA
DA neurons for basal and MK-801 evoked DA output in the MPFC. Dual-probe
microdialysis was used and the results were compared to those of corresponding
experiments on the DA release in the NAC.
TTX perfusion of the VTA (1 µM) significantly attenuated basal DA output in
both the MPFC and the NAC (Fig. 11). Thus, basal DA output in both these regions
appears entirely dependent upon action potential generation in the VTA.
Two hour TTX perfusion of the VTA abolished the effect of MK-801 on DA
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Fig. 11: Effects of TTX perfusion of the VTA on DA output in the NAC (A) and
the MPFC (B), as assessed by dual-probe microdialysis in freely moving rats. Gray
bars indicate TTX perfusion of the VTA. Arrows indicate the MK-801 injection.
release in the NAC (Fig. 11A) but not in the MPFC (Fig. 11B) where a significant 
increase was still observed.
In summary, the present data demonstrate that the increase in DA release in the
NAC evoked by systemic MK-801 is critically dependent on nerve impulses generated in
the VTA, i.e. it is largely caused by the increased neuronal activity in the VTA DA cells.
In contrast, the pronounced increase in DA levels in the MPFC evoked by MK-801 is
largely independent of action potentials generated in the VTA, as we had hypothesized.
In other words, this increase is in all probability due to facilitation of DA output at the
DA nerve terminal level in the MPFC. This facilitatory effect of systemic MK-801 on
DA output in the MPFC might be caused, at least partially, by decreased GABAergic
inhibition of DA terminals in the MPFC (Yonezawa et al. 1998). In addition, an EAA
mediated mechanism in the MPFC has been proposed (Moghaddam et al. 1997), since
local perfusion of the MPFC with the AMPA and kainate receptor antagonist CNQX
partially attenuated systemic ketamine induced DA release in this brain region (cf.
below). Our results indicate that a major dysfunction of brain DA systems induced by
non-competitive NMDA receptor antagonists is the uncoupling of the mesocortical DA
projection from its basal, physiological regulation by nerve impulse generation at the
level of the VTA, in particular as regards its functionally most important mode, i.e. burst
firing. However, the mechanism for the increased, burst-like firing of subcortically
projecting VTA DA neurons in the PN induced by these drugs remained to be clarified.
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IV: Significance of AMPA and kainate receptors in the ventral tegmental area for basal and MK-801
evoked dopamine release in the nucleus accumbens and locomotor stimulation 
(Paper V)
During the experiments described in section I, we observed an unexpected
increased neuronal activity and, particularly, burst-like firing in VTA DA neurons in the
PN following administration of PCP or MK-801. This was associated with a markedly
increased DA release in the major projection area of the VTA PN neurons, the NAC
(see section II & III). Since burst firing had been shown to depend on tonic activation
of NMDA receptors in the VTA, the mechanism of the high frequency burst-like firing
remained obscure. Although NMDA receptor in different anatomical localizations might
be involved, significant NMDA-, AMPA-, and kainate receptor binding had been
demonstrated in the VTA (Albin et al. 1992). We observed a marked similarity between
the MK-801 induced firing pattern in VTA DA neurons in the PN and that obtained
following local microiontophoretic application of the AMPA and kainate receptor
agonists quisqualate and kainate (Chergui et al. 1993). Moreover, previous results
indicated that mesolimbic and mesocortical DA neurons are differentially modulated by
EAA receptor subtypes in the VTA: although the mesocortical DA projection appeared
largely modulated by NMDA receptors, subcortically projecting VTA DA cells seemed
primarily regulated by the AMPA and kainate subtypes of EAA receptors (Kalivas et al.
1993). Thus, we hypothesized that the high-frequency burst-like firing in the PN
neurons of the VTA following systemic PCP or MK-801 might be caused indirectly by
means of activation of AMPA and/or kainate receptors in the VTA, an effect that also
could be responsible for the increased DA release found in the NAC. Therefore, in this
series of experiments we assessed to what extent local application into the VTA of an
AMPA and kainate receptor antagonist, CNQX, could antagonize the evoked DA
release in the NAC and the associated behavioral stimulation caused by systemically
administered MK-801. MK-801 evoked behaviors were assessed by direct observation in
conjunction with the ongoing microdialysis experiments, i.e. locomotor activity, turning,
head weaving, sniffing and ataxia.
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Fig. 12: Effects of local perfusion of the VTA with the AMPA and kainate
receptor antagonist, CNQX, on systemic MK-801 evoked DA release in the NAC
as assessed by microdialysis (A) and typical MK-801 evoked behaviors (B).
Perfusion of the VTA with CNQX for forty minutes effectively antagonized the 
increase in DA output in the NAC evoked by subsequent systemic MK-801
administration in a concentration-dependent manner. When the highest concentration
of CNQX was used, i.e. 1 mM, systemic administration of MK-801 completely failed to
affect DA output in the NAC (Fig. 12A). In addition, we observed that animals perfused
with CNQX in the VTA exhibited significantly shorter periods of locomotor activity
following MK-801 injection. None of the other measured MK-801 evoked behaviors
was affected by CNQX perfusion of the VTA (Fig. 12B). Perfusion of the VTA with the
AMPA and kainate receptor antagonist CNQX (300 µM and 1 mM) alone did not
significantly affect DA output in the NAC, nor did it cause any change in the rated
behaviors.
Consequently, MK-801 evoked locomotor activity and DA release in the NAC
appear critically dependent upon AMPA and/or kainate receptor activation in the VTA.
Indirectly, this finding suggests that MK-801 causes an augmented EAA input to the
VTA neurons, a notion that has gained some support from preliminary results,
demonstrating an apparently increased extracellular concentration of glutamate and
aspartate in the VTA following s.c. administration of MK-801, 0.1 mg/kg (Svensson et
al. 1998A). In fact, the non-competitive NMDA receptor antagonist ketamine has
recently been shown to elevate extracellular concentrations of glutamate in the MPFC
(Moghaddam et al. 1997). Our behavioral results are indirectly supported by Narayanan
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et al. (1996), data demonstrating that local inhibition of VTA neuronal activity with the
GABAB agonist baclofen also antagonizes the increase in locomotion caused by systemic
MK-801. In addition, in the same study local bilateral microinjection of MK-801 into the
VTA was found to mimic the behavioral effects of systemic MK-801 injection. Thus,
both the locomotor stimulatory and the DA releasing effects in the NAC of systemic
MK-801 seem to be elicited within the VTA. By inference, our present and previous
findings suggest that the hyperlocomotion caused by systemic MK-801 is causally related
to the increased DA output in the NAC which, ultimately, is due  to the AMPA and/or
kainate receptor mediated increase in DA neuronal activity. 
In summary, the data presented in this section show that the dose-dependent
high frequency activation of mesolimbic DA neurons, induced by low doses of
systemically administered MK-801 (see section I) represents the major underlying
mechanism both for the associated increased DA release in the NAC and the ensuing
hyperlocomotion. Moreover, the burst-like activation of the subcortically projecting DA
neurons of the PN subdivision of the VTA is indirectly mediated via activation of
AMPA and/or kainate receptors in the VTA. Most significantly, although CNQX,
locally applied to the VTA effectively suppressed both the DA releasing effect and the
hyperlocomotion induced by administration of MK-801, it did not affect basal DA
release or spontaneous locomotor activity. Since antagonism of hyperlocomotion
induced by PCP-like drugs has been shown to be of some predictive value in assessment
of putative antipsychotic drugs (see Ögren et al. 1996), we hypothesized that AMPA
and/or kainate receptor antagonists might possess antipsychotic activity. This idea was
also proposed by other researchers, and was in those cases based upon behavioral
evidence alone (see section VI). The present study supports a causal relationship
between the MK-801 induced DA release and the associated behavioral stimulation and,
hence, provides evidence for a presynaptic DA inhibitory effect of the AMPA and
kainate receptor antagonists, an action that might act synnergistically with DA receptor
blockade to suppress psychotic symptomatology.
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V: Tentative antagonistic action of a1- adrenoceptor blockade on MK-801 evoked dopamine release in
the nucleus accumbens and behavioral stimulation (Paper IV)
Previous results infer blockade of other excitatory inputs to the VTA might
suppress the behavioral stimulation as well as the evoked accumbal DA release caused by
the psychotomimetic NMDA receptor antagonists. Since several studies from this
laboratory provided evidence for a noradrenergic excitatory regulation of VTA DA
neuronal activity, the putative utility of blocking this  a1-adrenoceptor mechanism was
explored. 
Nearly all clinically utilized antipsychotic drugs display a1-adrenoceptor
antagonistic properties, in addition to their DA-D2 receptor blocking action (see
Carlsson & Lindqvist 1963, Peroutka & Snyder 1980, Cohen & Lipinski 1986). Although
brain noradrenergic hyperactivity has been proposed in schizophrenia, especially
preceding and during acute psychotic relapse, the putative contribution of a1-
adrenoceptor antagonism to the antipsychotic efficacy of neuroleptics remains to be
established (van Kammen & Kelley 1991, Maas et al. 1993, van Kammen et al. 1994).
In initial electrophysiological experiments we observed that the increased burst-
like firing in subcortically projecting VTA DA neurons induced by systemic MK-801
could be effectively suppressed by subsequent administration of prazosin (Svensson et
al. 1995). In the present experiments we therefore studied the modulation by prazosin of
MK-801 effects on output of DA and its metabolites in the NAC, as assessed by
microdialysis, and on locomotor activity. The two doses of MK-801 chosen were 0.1
mg/kg s.c., a dose which has been shown to evoke hyperlocomotion which is highly
sensitive to catecholamine depletion, and 0.3 mg/kg, s.c., reported to represent the
highest dose which may be administered to rats without concomitant induction of
severe ataxia (cf. Criswell et al. 1993).
Systemic administration of MK-801 caused significant 60% overall increase in
output of DA and its metabolites in the NAC that reached a plateau approximately three
hours after injection (Fig. 13A). The magnitude and time course of effect of MK-801
was essentially identical for the two doses, suggesting that already at 0.1 mg/kg a
maximal DA release in the NAC was achieved (data not shown). MK-801 administration
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Fig. 13: Effects of systemic pretreatment with the a1-adrenoceptor antagonist,
prazosin, on MK-801 evoked DA release in the NAC (A) and on locomotor
activity (B). Arrow indicates MK-801 injection. 
also caused dose-dependent increases in dialysate concentrations of DOPAC and HVA,
with a time course that parallelled that of DA, as well as a significant and dose-
dependent increase in horizontal locomotor activity (Fig. 13B). However, similarly to
PCP, MK-801 also reduced rearing in dose-dependent manner. An increased
contribution of non-DA dependent mechanisms to the generation of hyperlocomotion
when higher doses (i.e. >0.25 mg/kg s.c. to rats) of MK-801 are used (see Carlsson &
Carlsson 1989) is supported by the finding that the higher dose of MK-801 increased
locomotor activity further while DA output in the NAC was not additionally augmented
compared to the effects of the low dose. 
Prazosin administration alone did not affect basal DA output in the NAC or
horizontal locomotor activity. However, it significantly reduced rearing. In contrast,
pretreatment with prazosin for twenty minutes significantly attenuated the elevation in
DA output in the NAC induced by both doses of MK-801 and significantly antagonized
MK-801 evoked increases in locomotor activity.
In summary, the present data demonstrate that systemic administration of MK-
801 significantly augments DA output in the NAC, in accordance with previous
microdialysis data (see section III, Wolf et al. 1993). Moreover, systemic pretreatment
with the a1-adrenoceptor antagonist prazosin, did not affect basal locomotor activity or
DA output in the NAC, but blocked both the evoked DA release in the NAC and the
behavioral stimulation caused by MK-801, effects which thus seem to be causally related.
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Since prazosin also blocked the MK-801 induced intense burst-like firing in the VTA
DA neurons projecting e.g. to the NAC, these results are in consonance with the view
that both the observed biochemical and behavioral effects are causally related to the
evoked neuronal activity in the subcortically projecting VTA DA cells. One mechanism
that may be involved in the suppression of MK-801 evoked DA output is that prazosin
blocks the excitatory a1-adrenoceptors within the VTA. However, a1-adrenoceptors in
other parts of the brain might also be involved. Thus, a1-adrenoceptor antagonism
appears to specifically inhibit evoked, but not basal, DA output, an effect which may be
of clinical interest, in view of the recent evidence for an enhanced evoked DA release in
vivo in striatal tissue of schizophrenic patients (Laruelle et al. 1996, Breier et al. 1997).
Therefore, the a1-adrenoceptor blocking action of most clinically available antipsychotic
drugs may well contribute to their overall DA antagonistic actions at a presynaptic level.
Since brain noradrenergic neurons, e.g. of the LC, are known to be activated by stress
(Foote et al. 1983), and environmental stress has been claimed to contribute to
precipitation or aggravation of psychotic behavior or relapse (van Kammen & Kelley
1991, Maas et al. 1993, van Kammen et al. 1994), the a1-adrenoceptor blocking action of
most antipsychotics, which with some drugs such as clozapine is very prominent, may be
particularly valuable during conditions of environmental stress or at the beginning of a
psychotic episode.
VI: Effects of AMPA receptor antagonism on the conditioned avoidance response and on catalepsy score
(Paper VII) 
In the previous experiments, we observed that AMPA and/or kainate receptor
antagonists block both behavioral stimulant and central, dopaminergic effects of
psychotomimetic NMDA receptor antagonists (see section IV, Willins et al. 1993,
Bubser et al. 1995, Vanover 1998). These studies suggest, although their predictive value
of this type of behavioral studies with regard to antipsychotic efficacy seems not to be
conclusively established, that AMPA and/or kainate receptor antagonists may possess
antipsychotic efficacy. Since suppression of the conditioned avoidance response (CAR)
is a behavioral effect that is shared by all effective antipsychotics, and potencies in the
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Fig. 14: Effects of the AMPA receptor antagonist,
LY326325, on the conditioned avoidance response.
 CAR test are highly correlated with and specifically predict therapeutic efficacy in
schizophrenia (Janssen et al. 1965, Arnt 1982), we decided to study the effects of
systemically administered AMPA receptor antagonists within this experimental
paradigm. Interestingly, systemic administration of GYKI52466, a non-competitive
AMPA receptor antagonist, was found to cause a significant suppression of CAR in the
rat, without any effect on escape behavior (Svensson et al. 1998B). Therefore, in the
present study we analyzed the putative effect of LY326325, a novel and specific AMPA
receptor antagonist, on CAR performance. In parallel experiments we studied its
tentative cataleptogenic properties, since the induction of catalepsy is generally
recognized and utilized as a predictive test for EPS liability of antipsychotics or
potentially antipsychotic drugs.
Our experiments revealed a reduction in avoidance behavior induced by systemic
administration of LY326325, 18 mg/kg, s.c., which was significant at 90 min following
injection (Fig. 14), without any impairment of escape behavior and, in fact, no response
failures were observed. LY326325 did not affect CAR when given at 6 mg/kg s.c.
Moreover, LY326325 did not cause significant catalepsy. When given in high doses
LY326325 (18 mg/kg, s.c.) caused some reduction of spontaneous locomotion and mild
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ataxia, although no significant change in inter-trial crosses was obtained. However, a
selective suppression of CAR is a specific effect of antipsychotic drugs which cannot be
attributed to a general sedative action of the drugs (Courvoisier 1957, Verhave et al.
1958).
In summary, LY326325 exhibits a pharmacological profile consonant with 
antipsychotic efficacy, as assessed by the CAR paradigm, an effect which is similar to our
recent results obtained with the non-competitive AMPA antagonist, GYKI52466. Since
two chemically different AMPA receptor antagonists were both found to cause selective
suppression of CAR, our findings provide strong support for the notion that AMPA
receptor blockade is the mechanism involved. These results were obtained without any
significant general attenuation of locomotor activity, thus indicating that the suppression
of CAR was not related to impairment of locomotion per se. Moreover, since LY326325
did not cause significant catalepsy, it may not cause extrapyramidal side effects, in
contrast to classical antipsychotic drugs. Previous studies have emphasized that clozapine
more effectively ameliorates the behavioral effects of PCP-like drugs than classical
antipsychotic drugs, including superior efficacy against hyperlocomotion and
stereotypies, as well as amelioration of deficits in delayed alternation performance
(Tiedtke et al. 1990, Hoffman 1992, Hauber 1993). Since LY293558, another structurally
similar AMPA receptor antagonist, has been shown to attenuate cognitive deficits
induced by ketamine, as assessed by delayed alternation (Moghaddam et al. 1997), the
antipsychotic efficacy of AMPA receptor antagonists may also include cognitive
symptoms. Thus, LY326325 appears to possess a pharmacological profile that is more
similar to the atypical antipsychotic profile of clozapine than to that of classical
neuroleptics.
58
General Discussion
In 1959, Luby et al. described the astonishing finding that an intravenous
injection of PCP to healthy volunteers even within an hour could elicit a mental state
that was virtually indistinguishable from the primary symptomatology of acute
schizophrenia, including e.g. auditory hallucinations and formal thought disorder, but
also blunted affect (see Javitt & Zukin 1991). Moreover, administration of subanesthetic
doses of PCP to a small group of chronic schizophrenic patients was reported to
reinstate the symptomatology of the acute, agitated form of the illness. Such
psychotomimetic properties have subsequently been found to be shared by all clinically
evaluated NMDA receptor antagonists (cf. introduction, Kornhuber & Weller 1995).
Consequently, it can be assumed that the behavioral state modelled by acute
administration of PCP-like drugs may reflect pathophysiological mechanisms in brain
that are involved at the onset of schizophrenia. Since early effective treatment might
possibly contribute to reduce continued deterioration frequently associated with chronic
schizophrenia (Remington et al. 1998, Wyatt et al. 1998), such initial pathophysiological
mechanisms may be of particular importance in the search for novel pharmacological
strategies to treat schizophrenia at an early stage of illness. Generally, our findings show
that following acute systemic administration of low, non-ataxic doses of
psychotomimetic NMDA receptor antagonists, such as PCP or MK-801, a profound
amd differential dysregulation of the mesolimbic and mesocortical DA systems occur.
Since several sets of experimental data show that major behavioral effects of low doses
of these drugs in the rat, tentatively relevant to the human experience, are mediated
largely via brain catecholamines, in particular DA, which exerts a pivotal role in the
control of psychotic symptomatology, the precise nature of these dysregulations has a
considerable interest. 
Our findings demonstrate a general deficit in the NMDA receptor mediated
phasic neuronal activation of mesocorticolimbic DA neurons and markedly reduced
variability of firing, superimposed upon an increased basal activity, i.e. a reduction in the
signal-to-noise ratio in DA signalling. Also previously, dopaminergic dysfunction in
schizophrenia has been proposed to involve a generally inappropriate modulation of DA
responsiveness to environmental stimuli, although in this case all stimuli were
hypothesized to elicit a maximal phasic DA release, an effect elicited essentially at the
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DA nerve terminal level in the VSTR (Grace 1993). However, more recent results have
emphasized the importance of corticofugal EAA inputs to the VTA in the reward and
stress related augmentation of DA output in the NAC, i.e. phasic nerve impulse
mediated responses mediated by EAA receptors in the VTA (Murase et al. 1993, Taber
et al. 1995, Murphy et al.1996, Westerink et al. 1997, Enrico et al. 1998). In fact, a
previous study from our laboratory directly demonstrated a decreased sensory
responsiveness of other catecholamine neurons in the brain, i.e. in the LC, which
receives an EAA input from the MPFC (Jodo & Aston-Jones 1997, Jodo et al. 1998),
following systemic administration of PCP or MK-801. These neurons also displayed a
reduced varability of firing, but an increased basal firing rate (Murase et al. 1992). These
findings support the notion of a general reduction of dynamic neuronal responsivity to
environmental stimuli of central catecholamine neurons. Our present results support the
contention that the augmentation of subcortical DA output induced by MK-801 largely
is elicited in the VTA, and that it is nerve impulse dependent. Thus, the dysregulations
of DA neuronal activity induced by PCP-like drugs indicate that an augmented tonic, but
attenuated phasic DA neuronal signalling in the mesolimbic DA projection may be
associated with the onset of psychotic symptoms. Such a dysregulation might well have
bearing on symptoms such as emotional blunting and motivational dysfunction. Since a
dysregulation of DA signalling also was observed in the nigrostriatal DA projection, a
neuronal pathway inter alia regulated by proprioceptive inputs and fundamentally
involved with the specific control of movements and posture (Romo & Schultz 1989),
and an even more pronounced dysregulation was observed in the prefrontal DA
projection, a brain region heavily involved with cognitive and integrative functioning, an
imbalance emerges within the striato-pallido-thalamo-cortical circuitry that may
tentatively have bearing on primary symptoms such as disturbances of body image and
depersonalization.
Our findings demonstrate that the locomotor hyperactivity induced by acute
systemic administration of low doses of MK-801 is associated with, and largely
dependent upon, augmentation of DA output in the NAC, in similarity to the
psychostimulant effect of D-amphetamine. Previously it has been postulated that
hyperlocomotion induced by psychotomimetic drugs may primarily reflect mechanisms
involved in the generation of positive symptoms of schizophrenia (see Martin 1998).
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Dopaminergic mechanisms have also been implicated in various other PCP induced
behaviors in rodents, e.g. hyperlocomotion, some stereotypies, impaired cognitive
function and deficits in social behavior vide supra (Murray & Horita 1979, Fessler et al.
1980, Clineschmidt et al. 1982, Gratton et al. 1987, Ögren & Goldstein 1994, Steinpreis
et al. 1994, Jentsch et al. 1997). Needless to say, not all MK-801 evoked behaviors were
attenuated by reduction of concomitant DA output in the NAC since, for example, head
weaving and sniffing were not affected. Consequently, some of these effects, e.g.
stereotyped behaviors, may instead be related to augmentation of DA output in
nigrostriatal DA terminal regions, e.g. dorsolateral striatum (Miller & Abercrombie
1996), or to non-dopaminergic mechanisms. Thus, PCP and MK-801 evoked head
weaving has been shown to be related to enhanced 5-HT1A receptor activity (Yamaguchi
et al. 1987, Löscher & Hönack 1992), and our experiments showed that reduction of
rearing, as induced by systemic administration of PCP, appears to be temporally related
to the increase in NT output in the VSTR. In addition, higher, ataxic doses of MK-801
have been reported to evoke pronounced locomotor activity also in monoamine-
depleted mice (Carlsson & Carlsson 1989), although the threshold dose was subsequently
shown to be approximately tenfold higher than that in monoamine-intact animals
(Martin et al. 1994). These observations are not, in principle, contradictory to our
findings in rats. Rather, following the probably more extensive NMDA receptor
blockade induced by high ataxic doses of MK-801, local EAA mechanisms within the
NAC may contribute to further exaggerate behavioral output in a manner which is
functionally disconnected from the DA release process (see Carlsson 1993). Several lines
of evidence indicate that in schizophrenia impairments of the connectivity and
synchronization of discrete brain regions may facilitate the generation of abnormal
output from these structures, e.g. contribute to the emergence of local “ectopic foci”,
which autonomously generate abnormal behaviors (Weinberger 1987, Hoffman &
McGlashan 1994). Tentatively, the presently observed differential dysregulations of
mesolimbic and mesocortical DA neurons may be seen as an early sign of such regional
desynchronization. Physiologically both DA projections are largely regulated at the VTA
level. However, administration of PCP-like drugs largely shifts this control of the
mesocortical, but not the mesolimbic, DA projection to a local control mechanism
within the PFC region. Thus, the PFC becomes functionally more autonomous in
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comparison to subcortical structures such as the ventral striatum. Consequently, the
emergence of DA independent behaviors with very high doses of NMDA receptor
antagonists might constitute a pharmacological model of more chronic schizophrenia,
whereas the largely DA dependent behavioral abnormalities, acutely obtained with low,
non-ataxic doses of these drugs, rather might reflect pathophysiological mechanisms that
may be involved in the onset of acute psychosis. The clinical observation that acute
psychotic states generally are more responsive to treatment with DA-D2 receptor
antagonists than chronic schizophrenia is clearly compatible with this notion. A logical
consequence of this notion is that pharmacological treatment at the early onset of
schizophrenia might require somewhat different drugs than those currently used to
combat the chronic disorder (see below). Potentially, the acute PCP model of
schizophrenia could therefore help to identify such drugs.
Repeated PCP administration, similarly to acute administration, is associated with
profound cognitive deficits, although the effects of chronic administration appear more
long-lasting and severe than those observed following a single injection. Also non-
human primates exposed to chronic PCP exhibit marked cognitive impairment, a
phenomenon associated with reduced DA turnover in the MPFC (see Jentsch et al.
1998). Consequently, these data indicate that a dysregulation of the mesocortical DA
system may play a role in the behavioral actions of PCP also in primates, and vide infra
also in schizophrenia, as previously suggested (Weinberger 1987, Svensson et al. 1993).
Cognitive impairments have also been observed in rats following acute administration of
PCP-like drugs, but were associated with an increased DA output in the MPFC (present
study, Verma & Moghaddam 1996, Moghaddam et al. 1997). However, several lines of
evidence indicate that PFC functioning may be highly sensitive to changes in DA
receptor activation, whether increased or decreased (Brozoski et al. 1979, Sawaguchi &
Goldman-Rakic 1994, Murphy et al. 1996, Verma & Moghaddam 1996). Moreover,
optimal PFC function in relation to cognitive activity, e.g. executive function and
planning of behavior in a contextually relevant manner, seems not only to require
sufficient basal release of DA, but also adequate and transient variations of DA output in
response to reward-predicting stimuli or failure of reward prediction. In other words,
impulse dependent phasic alterations in VTA DA neuronal activity appear necessary for
adequate cognitive functions involving working memory as well as the general adaptation
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to novel situations (Sawaguchi & Goldman-Rakic 1994, Schultz et al. 1993, Schultz
1998). Therefore, the fact that in the MK-801 treated animal the physiological, impulse
dependent DA release in the MPFC has been largely replaced or superseded by locally
generated DA release within this brain region implies a dramatic change in the
physiological control of prefrontal dopamine release. Such a dysregulation of
mesocortical DA function should have particular behavioral impact in stressful situations
requiring rapid alterations in the signal processing characteristics of the postsynaptic
cortical neurons (Servan-Schreiber et al. 1990).
Pioneering studies in a neurodevelopmental model of schizophrenia, created by
neonatal lesions of the ventral hippocampus, have revealed in post-pubertal rats the
emergence of behavioral hyperresponsiveness to stress or DA agonists (see Lipska &
Weinberger 1993) and, in the adult lesioned rats, an increase in DA turnover in the
VSTR, concomitant with a decrease in the MPFC were observed (Lipska et al. 1995, see
Weinberger & Lipska 1995).  Thus, this neurodevelopmental model of schizophrenia,
perhaps particularly in the stressed state, offers an intriguing functional similarity with
the PCP-induced dichotomy in the dynamic function and dysregulation of the
mesocortical and the mesolimbic DA neurons.
In our previous experiments, the reduction of burst activity in the mesocortical
DA cells following MK-801 administration could be specifically reversed by subsequent
injection of the potent 5-HT2A-2C antagonist, ritanserin, which still did not affect the
tonic activity of the cells, i.e. their average firing rate (Svensson et al. 1995). In addition,
atypical antipsychotic drugs with potent 5-HT2A antagonistic properties, e.g. clozapine
and amperozide, preferentially augment DA output in the limbic cortical related sites
including the MPFC in rats (Moghaddam & Bunney 1990, Nomikos et al. 1994, Marcus
et al. 1996). These and other findings from this laboratory (e.g. Grenhoff et al. 1990)
suggest that 5-HT2A receptor antagonistic effect of atypical antipsychotics may
specifically help to improve the nerve impulse dependent, phasic signalling of cortically
projecting DA cells. Such an improvement of the timing of DA release in the PFC may
lead to an improved PFC functioning, which according to recent data appears to require
a precise timing and magnitude of DA release for effective cognitive behavior (Williams
& Goldman-Rakic 1997). A secondary consequence of an augmentation of phasic DA
output in the PFC is probably an associated reduction of DA output in striatal sites
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(Kolachana et al. 1995). Consequently, a facilitation of cortical DA functioning caused by
potent 5-HT2A antagonists, may indirectly suppress a hyperactive or hyperreactive
subcortical DA projection at the presynaptic level and, hence, act synergistically with
postsynaptic DA-D2 receptor antagonism.
 Our results, which may reveal fundamental pathophysiological mechanisms with
tentative bearing on the emergence of schizophrenia, might thus afford insights that
could prove useful to reveal novel strategies for pharmacological treatment of this
disorder. Several potential strategies could be utilized to reduce a hyperactive or
hyperreactive mesolimbic DA system and the concomitant behavioral activation without
directly antagonizing DA receptors. Our data suggest that one means of achieving such
an effect is antagonism of a1-adrenoceptors. The mechanism(s) may involve reduction
of VTA DA cell excitability by blocking an excitatory, noradrenergic input to the DA
cells and thus provide a presynaptic mechanism to antagonize the augmented subcortical
DA release. In fact, presynaptic attenuation of DA output has previously successfully
been utilized in the treatment of schizophrenia in clinical trials (Carlsson et al. 1973,
Walinder & Carlsson 1973) An obvious advantage of this strategy might be a reduced
risk of EPS, which is substantial with classical antipsychotics and directly reflects the
degree of postsynaptic DA-D2 receptor blockade (Farde & Nordström 1993). Another
putative advantage of this strategy is that a1-adrenoceptor blockade seems to
preferentially suppress evoked mesolimbic DA release and the associated behavioral
stimulation, leaving basal DA release and behavioral functions relatively undisturbed, as
demonstrated by our results. Prazosin has recently been shown also to prevent PCP
induced deficits in prepulse inhibition, a behavioral test considered to possess predictive
value in the assessment of putative antipsychotic efficacy (Bakshi & Geyer 1997).
Consequently, these findings suggest that a1-adrenoceptor antagonism may contribute to
antipsychotic activity. This is consistent with the a1-adrenoceptor antagonistic action of
a large number of antipsychotic drugs in general, and clozapine in particular. Although a
clinical trial reported that addition of prazosin to neuroleptic treatment of chronic
schizophrenic patients failed to augment the therapeutic effect of the ongoing treatment
(Hommer et al. 1984), this finding may relate to a relatively limited capacity of prazosin
to penetrate the blood-brain barrier in man (Pfizer AB, personal communication,
Cubeddu 1988, van Kammen & Kelley 1991), although it effectively does so in rodents.
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In addition, the fact that an antipsychotic drug was used in the study by Hommer et al.
(1994), that by itself possesses some a1-adrenoceptor antagonistic action might have
confounded the outcome of this study. Thus, a1-adrenoceptor antagonists with
improved capacity to enter the CNS might represent an intriguing pharmacological
principle to explore for its clinical usefulness, perhaps particularly at the onset of
schizophrenia. At any rate, our results suggest that even if such a1-adrenoceptor
antagonists were to be found ineffective in the management of schizophrenia when
given alone, the combination of effective central a1-adrenoceptor blockade with DA-D2
antagonists might imply a clinical advantage over DA-D2 antagonists given alone (see
Svensson et al. 1998B).
A second, novel pharmacological principle to treat psychotic disorders, that is
supported by our experimental results is the use of AMPA receptor antagonists. Thus,
following administration of MK-801, an augmentation of the EAA input to the VTA
seems to occur, which via stimulation of AMPA receptors in the VTA causes an
unphysiological activation of the mesolimbic DA neurons, as well as an increased DA
output in the NAC and concomitant behavioral stimulation. Our results, as well as those
of others, accordingly showed that local intra-VTA- as well as systemic antagonism of
AMPA receptors in turn antagonizes the PCP or MK-801 induced hyperlocomotion
(Willins et al. 1993, Bubser et al. 1995, Vanover 1998). On the basis of our findings that
the AMPA receptor antagonists attenuated the behavioral stimulation and also
suppressed the evoked DA release in the NAC, without effect on basal DA release or
behavior, we hypothesized that the AMPA receptor antagonists might possess an
antipsychotic potential. This notion gained substantial novel support from our
subsequent studies showing suppression of CAR by two, chemically different, AMPA
antagonists GYKI52466 (Svensson et al. 1998B) and LY326325, since CAR represents a
classical preclinical test of high predictability as regards the clinical antipsychotic effect of
experimental drugs. However, our observations indicate that side effects such as ataxia
might limit the usefulness of this type of compounds if high doses were to be needed
(Maj et al. 1995, Schoepp et al. 1995, Vanover 1998). Clearly, other preclinical
observations obtained with selective AMPA receptor antagonists, such as suppression of
the morphine withdrawal reaction at the level of the LC (Rasmussen et al. 1996), also
underline the potential usefulness of this type of drugs in psychiatry.
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A major consequence of the glutamate/dopamine dysregulation hypothesis of
schizophrenia may be that the objective for pharmacological treatment perhaps should
no longer be to generally block dopaminergic neurotransmission in brain, not even
selectively within the mesocorticolimbic DA system, a previous strategy used to
circumvent the EPS liability of antipsychotic drugs drugs. Rather, early pharmacological
intervention might aim at correcting a differential dysregulation of different DA
projections in brain. Our results lead to the heuristic hypothesis that the PCP induced,
psychotic symptomatology may not only be a direct consequence of reduced NMDA
receptor activation in brain, but also indirectly be a consequence of enhanced AMPA
receptor activation. Thus, a novel pharmacological treatment strategy in psychosis might
involve both facilitation of NMDA receptor function, e.g. as achieved by administration
of glycine (Heresco-Levy et al. 1996), and AMPA receptor antagonism. Clearly, this
pharmacological approach is different from that suggested by unifying theories for
antipsychotic drug action, such as the depolarization-block theory (see Grace 1993),
which apart from several points of technical criticism raised by other researchers
(Moghaddam & Bunney 1993, Mereu et al. 1995, Klitenick et al. 1996, Melis et al. 1998)
also fails to encompass the probable regional differences between the dysregulations of
mesocortical and mesolimbic DA systems as suggested by both the PCP model and the
neurodevelopmental model of schizophrenia. The finding that clozapine differentially
affects these two dopaminergic projections vide supra provides indirect support for this
notion (Moghaddam & Bunney 1990, Nomikos et al. 1994, Marcus et al. 1996). Perhaps,
in this way, clozapine may not only clinically, but also theoretically be regarded as a truly
pioneering antipsychotic drug.
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Summary
- Systemic administration to the rat of psychotomimetic NMDA receptor antagonists,
such as PCP and MK-801, similarly dysregulates the firing pattern of VTA DA neurons,
an effect which indicates that these effects of PCP are largely due to NMDA receptor
antagonism.
- VTA DA and SN-ZC neurons respond to systemic administration of PCP or MK-801
with an increased average firing rate and increased regularity of firing. Burst firing in
VTA DA neurons is differentially affected dependent upon the anatomical localization
of the DA neurons; essentially subcortically projecting VTA DA neurons in the PN
display a high frequency burst-like firing pattern, whereas VTA DA cells in the PBP,
which largely provide the DA innervation of the PFC, respond with a decreased phasic
burst activity. Thus, the temporal distribution of DA impulse activity in the mesolimbic
and mesocortical DA projections is dysregulated, which may impair the adequate
responsivity of the DA neurons to salient and reward predicting stimuli.
- Systemic administration of PCP and D-amphetamine significantly augments DA
output in the VSTR and MPFC, although D-amphetamine is more potent that PCP in
this regard. The spatial disorganization of behavior caused by systemic D-amphetamine
and PCP appears largely related to the DA releasing effects of these compounds. 
- Systemic administration of PCP and D-amphetamine also increases NT-LI levels in the
MPFC, although only PCP elevates NT-LI levels in the VSTR. In view of the
antagonistic action of NT on DA mediated behaviors in the VSTR, the capacity of PCP
to reduce rearing may, at least partially, be related to the increase in NT output in the
VSTR caused by PCP.
- The systemic MK-801 evoked stimulation of DA release in the NAC, a major terminal
area of the mesolimbic DA system, as well as concomitant locomotor stimulation, are
largely dependent upon the augmented nerve impulse activity in the DA neurons. These
effects seem dependent on increased AMPA and/or kainate receptor mediated
activation of DA neurons in the VTA.
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- The increased DA output in the MPFC evoked by systemic MK-801 is, instead, largely
independent of DA neuronal activity. Instead, it is probably caused locally within the
DA nerve terminal region. Thus, the mesocortical DA neurons become uncoupled from
their afferent regulation at the cell body level, an effect which may contribute to impair
the neuronally mediated, phasic responsivity of DA neurons to salient and reward
predicting environmental stimuli. 
- Systemic pretreatment with the a1-adrenoceptor antagonist prazosin significantly
attenuates both MK-801 induced DA release in the NAC and concomitant
hyperlocomotion. Thus, a1-adrenoceptor antagonism should reduce the impact of
noradrenergic activation of VTA DA neurons, an effect that may be particularly
important in association with pronounced environmental stress. Consequently, a1-
adrenoceptor antagonistic properties of antipsychotic drugs may act, presynaptically, in
concert with concomitant postsynaptic DA-D2 antagonism to specifically reduce evoked
subcortical DA hyperactivity.
- Administration of the AMPA receptor antagonist LY326325 suppresses the
conditioned avoidance response without effect on escape behavior, effects similar to
those of essentially all antipsychotic drugs. Simultaneously, LY326325 does not attenuate
general locomotor activity, nor does it cause significant catalepsy. The effects of
LY326325 are in these respects similar to those of clozapine rather than classical
antipsychotics and support the hypothesis that AMPA receptor antagonists may possess
an atypical antipsychotic profile.
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‘Curiouser and curiouser’, cried Alice
 (she was so much surprised that for the moment she quite forgot how to speak good English).
